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Targeting unique domains of LSD1 regulates pediatric glioma innate immunity and NK 
cell metabolism 
  
Cavan Paul Bailey, B.A. 
 




 Regulation of chromatin accessibility is a key mechanism of cellular identity, 
allowing different tissues to develop using the same DNA template. Cancers will often 
hijack these epigenetic pathways, reactivating developmental genes to drive growth and 
deactivating tumor suppressor and immune recognition genes. Chromatin-modifying 
proteins deposit and remove chemical moieties from histone tails to aid in governing 
gene expression, and these proteins have become a new therapeutic target in cancer. 
Traditional chemotherapeutics aim to damage DNA, dysregulate cell division, or block 
hormonal growth signals, but epigenetic therapy can target vulnerabilities specific to 
cancer cells and broadly change gene expression patterns that may aid new modalities 
such as immunotherapy. 
Pediatric high-grade gliomas (pHGGs) often possess mutations in histone coding 
genes that cause aberrant histone methylation and gene expression. Cells derived from 
these patient’s tumors display growth inhibitory sensitivity to epigenetic drugs targeting 
histone deacetylases and methyltransferases, but other epigenetic targets remain 
unexplored in this cancer. The histone demethylase LSD1 (also known as KDM1A, 
BHC110, and KIAA0601) has been revealed as a promising target in leukemias and 
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pediatric sarcomas, but its validity as a cancer target in pediatric glioma is unknown. 
LSD1 can be inhibited by small molecules with unique mechanisms of action, binding to 
either the catalytic site directly, or to an allosteric interface region. These LSD1 
inhibitors produce differing effects in various cell types, dependent on LSD1-interacting 
proteins and how these interactions are disrupted by inhibitor binding.  
Through testing of a suite of catalytic and scaffolding LSD1 inhibitors, I have 
revealed LSD1 as an immune-regulatory target in pHGG, and as a potential mediator of 
metabolism and redox balance in natural killer (NK) cells. Furthermore, using 
bioinformatics approaches, I reveal differences in pHGG immune infiltrate by tumor 
location that may govern future treatment with LSD1 inhibitors or other 
immunostimulatory agents. This thesis collectively demonstrates that LSD1 is a valid 
therapeutic target in pHGG, and that inhibiting distinct structural domains of LSD1 
boosts innate immune reactivity in pHGG and modulates the metabolism and oxidative 
stress of NK cells. My work sets the stage for clinical translation of a combination pHGG 
therapy using an LSD1 inhibitor with NK cell infusion. 
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Discovery, structure, and function of LSD1 
Discovery of LSD1 
Histones are DNA-interacting proteins that package the double helix DNA strand 
into a compact structure in a cell’s nucleus. Gene regulation can be governed by this 
higher order chromatin structure, with “open” chromatin being more accessible than 
“closed” or tightly-packed chromatin. While histones serve a structural role in chromatin 
packaging, they also are regulatory, with post-translational modifications able to 
influence gene expression by recruiting transcription factors and changing chromatin 
shape. These tails are modifiable at conserved amino acid residues by acetylation, 
methylation, phosphorylation, ubiquitination, and several other chemical modifications. 
Histone acetylation by histone acetyltransferases (HATs) and histone deacetylases 
(HDACs) was first delineated by the isolation of the HAT GCN5/KAT2A (1) and HDAC1 
(2) in 1996. These opposing enzymes function dynamically to regulate acetylation 
marks that repel one another and “open up” chromatin regions. Histone methylation was 
known to exist, but it was unknown if it could be removed by enzymes akin to HDACs. 
The lab of Yang Shi at Harvard Medical School was the first to functionally describe a 
histone demethylase, at the time called KIAA0601 and BHC110, but renamed lysine-
specific demethylase 1 or LSD1 (3). They identified it as related to amine oxidases, with 
which LSD1 shares a common chemical mechanism for demethylation, which requires 
flavin adenine dinucleotide (FAD) as a cofactor and produces hydrogen peroxide and 
formaldehyde as byproducts (Fig 1). They also made the important discovery of 
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substrate specificity, in which LSD1 can only demethylate di-methylated histone 3 lysine 
4 (H3K4me2) and not the trimethylated form.  
LSD1-interacting proteins 
The Shi lab later identified HDAC, CoREST, and BHC80 as interacting proteins 
with LSD1 that could regulate its activity (4) (Fig 1). HDACs were necessary to 
deacetylate histones ahead of LSD1 binding, which was weaker with hyperacetylated 
histones. CoREST was an important stabilizing factor, preventing LSD1 proteasomal 
degradation and stimulating LSD1 activity. BHC80, meanwhile, has repressive activity 
towards LSD1. CoREST’s positive regulation of LSD1 binding to nucleosomes was 
shown by the Shiekhattar group, which also identified lysine-661 as a key residue 
needed for LSD1 demethylase activity (5). The same group later showed that LSD1 
activity cooperates with HDAC1 activity via physical interaction with CoREST (6). 
Although LSD1 can normally only demethylate H3K4, it was found that LSD1 can 
complex with androgen receptors to change its specificity to H3K9 (7). Other key 
interacting proteins of LSD1 were found to be GFI1 and the related GFI1b, which 
required the SNAG domain to complex with LSD1 and CoREST (8) (Fig 1). Methylation 
of the SNAG domain at lysine-8 on GFI1 controlled its binding to LSD1 (9). Notably, it 
was found that LSD1 can also demethylate non-histone substrates, including the tumor 
suppressor p53 (10, 11). Long-noncoding RNA, or lncRNA, were seen to bridge the 
LSD1 complex with the histone methyltransferase PRC2 complex (12).  
Structural domains of LSD1 
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An LSD1 crystal structure was published in 2006, defining 3 main domains: 
tower, SWIRM, and amine oxidase (13). The SWIRM domain is separate from the 
active site but is critical to catalytic activity, so it was hypothesized to serve as a 
stabilizing domain. The amine oxidase domain binds cofactor FAD and histone tails to 
catalyze the demethylation reaction. In addition, the oxidase domain was shown to be 
the region that SNAG domains bind to LSD1 (Fig 1). These SNAG domains are present 
on Snail1 (14, 15), GFI1 (8), and other transcription factors and regulates their 
positioning on the genome. The tower domain was shown to interact with complex 
member protein CoREST (16), and CoREST binds to DNA via its SANT2 domain which 
specifies and regulates LSD1 demethylase activity (17) (Fig 1). The tower and oxidase 
domains play unique roles in different tissue types, which will be explored in sections 
below. 
LSD1 in development and hematopoiesis 
Epigenetic signaling is key to normal mammalian development, as each contains 
the same DNA sequence but must differentiate into many unique cell types. LSD1 was 
implicated in gastrulation during mouse embryogenesis, and embryos deleted for LSD1 
do not survive. Mechanistically this was mediated by LSD1 demethylating DNMT1, 
increasing DNMT1 stability, and enabling normal DNA methylation to be inherited during 
cell division (18). Mouse embryonic stem cells deleted for LSD1 were able to proliferate 
normally, as LSD1 is required only in the epiblast stage. The LSD1-null embryonic cells 
possessed lower expression of CoREST and alterations in expression of limb patterning 
genes (19). Developmental transcription factors NANOG and OCT4 were regulated by 
LSD1 maintenance of H3K4 methylation with H3K27 methylation (20). This was further 
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defined with functions of LSD1 in binding to enhancers during development (21). In the 
brain, neuro-specific isoforms of LSD1 are involved in normal neural development, 
particularly of neurons (22). Neural precursor cells were found to be reliant on LSD1 
activation of Atrophin1 to become mature neurons (23). Inner ear progenitor cells also 
require LSD1 to interact with transcription factor cMyb to develop normal ear function 
(24).  
LSD1 was implicated in normal blood function as a cooperative member, along 
with the Blimp-1 transcription factor, in plasma cell differentiation from mature B-cells 
(25). GFI1 and GFI1b are transcription factors involved in red blood cell (RBC) 
(erythropoiesis) and platelet (megakaryopoiesis) production, and they were found to 
cooperate with the LSD1 complex to direct gene expression and maturation of RBC and 
platelet progenitors (8, 26). This interaction would later be found to be vitally important 
for therapeutically targeting LSD1 in blood cancers, which is detailed in the next 2 
sections (Fig 1). Two landmark papers were published in 2012 and 2013 using LSD1 
knockout mouse models that examined hematopoiesis in detail. An inducible LSD1 
knockdown model displays lack of LSD1 in all tissues, and produced expansions of 
granulocyte, RBC, and platelet progenitors but contraction of mature versions of these 
cell types (27). Notably, this phenotype could be reversed by LSD1 re-expression. A 
following report used a tissue-specific knockout of LSD1 that deleted the catalytic site of 
LSD1 in the hematopoietic system. Compromised development of both early and late 
hematopoietic cells was observed, and use of chromatin-immunoprecipitation 
sequencing showed LSD1 could no longer bind to and silence promoters and 
enhancers required for normal development (28). Later it was shown that 
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overexpression of LSD1 in hematopoietic stem cells could “prime” them for malignant 
transformation when subjected to radiation (29). LSD1 silencing of endothelial genes in 
the aorta–gonad–mesonephros region was shown to be required for the earliest 
emergence of hematopoietic stem cells from transient hemogenic endothelium (30). B-
cells were again tied to LSD1, both in plasma cell differentiation mechanisms (31) and 
marginal zone B-cell development (32). A detailed study found that the tower domain of 
LSD1, but not its catalytic activity, was needed for germinal center B-cell development 
by direct interactions with BCL6 at intergenic enhancers (33). This finding shows that 
LSD1 plays lineage-specific roles in the hematopoietic system, with the catalytic 
domain-GFI1 interaction needed for RBCs and platelets, and a tower domain-BCL6 







Fig 1. Protein model of LSD1 in complex with CoREST, GFI1, and co-factor FAD. 
PyMOL was used to generate images for export, which was further labeled in 
PowerPoint. LSD1 in complex with CoREST and SNAG domain was visualized using 
Protein Data Bank accession 2Y48. GFI1 in complex with DNA was visualized using 
Protein Data Bank accession 2KMK.  
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Role of LSD1 in cancer 
LSD1 in leukemias 
The earliest report of LSD1 playing a functional role in leukemia is a 2009 report 
of LSD1 interacting with transcription factor TAL1 as part of its greater complex 
(LSD1/CoREST/HDAC1/HDAC2). They found that TAL1 in association with this 
complex can circumvent differentiation programs to erythroid cells and maintain a stem-
like state in murine erythroleukemia (34). A later finding was that serine 172 on TAL1 
was critical to the TAL1-LSD1 interaction and was mediated by protein kinase A (PKA) 
(35). In 2012, two instrumental papers were published showing that LSD1 is a valid 
therapeutic target in acute myeloid and MLL-AF9 fusion leukemias, using LSD1 
inhibitors to block LSD1 demethylase activity (36, 37) (inhibitors discussed in detail in 
next section). CD86 expression was soon after proposed as a reproducible biomarker of 
LSD1 inhibition in leukemias (38). Combination therapy of an LSD1 inhibitor with HDAC 
inhibition was shown to be efficacious against acute myeloid leukemia (39). MLL-
rearranged leukemias were sensitive to combination of LSD1 and DOT1L (an H3K79 
methyltransferase) inhibitors (40). The most recent reports examining combination 
therapies with LSD1 inhibition include use of DNA methyltransferase inhibitors (41), 
bromodomain inhibitors (42), and mTORC1 inhibition (43). 
In the past few years, multiple reports have shown that interactions with genomic 
elements are critical to the efficacy of LSD1 inhibition in leukemias, particularly 
regulation of enhancers and transcription factors. Takeda Pharmaceuticals developed 
an LSD1 inhibitor (T-3775440) that disrupts the LSD1-GFI1 interaction and was 
particularly effective against erythroid and megakaryoblastic leukemias (44). Activation 
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of super enhancers, which was dependent upon GFI1 presence, was the genomic 
mechanism of LSD1 inhibitor NCD38 efficacy in multiple leukemia subtypes (45). 
Recently it was further discovered that the LSD1-CoREST-HDAC complex can 
transcriptionally regulate GFI1 by binding to a GFI1 super enhancer (46). Enhancer 
activation under LSD1 inhibition was later shown to be directly dependent on GFI1-
LSD1 disruption, acetylation of histones around enhancers, and subsequent reading of 
histone acetylation by bromodomains (47). Differentiation of MLL-rearranged leukemia 
after treatment with LSD1 inhibitor was dependent upon the transcription factors PU.1 
and C/EBP-alpha (48). This finding was confirmed by another group, who also found 
that a catalytic-null form of LSD1 can induce differentiation of leukemia cells but not 
extend survival of mice (49). A hypothesis for this is that catalytic inhibitors block GFI1-
LSD1 associations, previously shown to be crucial for anti-leukemic effects, but a 
mutation in the catalytic site will not produce the same phenotype. A non-catalytic LSD1 
inhibitor SP-2509, discussed in detail in the next section, did not induce differentiation 
but was potently cytotoxic in vitro. CRISPR suppressor scanning of LSD1 later 
confirmed that its interaction with GFI1 is needed for efficacy of catalytic LSD1 
inhibitors, and the charged phenylalanine-5 residue of GFI1 controls disruption of GFI1-
LSD1 binding under inhibitor treatment (50).  
LSD1 in solid tumors 
Early clues to the role of LSD1 in maintenance and development of solid cancers 
was shown by the ability of LSD1 knockdown and inhibition to slow growth and induce 
differentiation of neuroblastoma (51). LSD1 was positively prognostic in breast cancer 
where it could reduce metastasis as a member of the NuRD complex (52). Despite this 
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finding, it was found LSD1 inhibitors were synergistic with HDAC inhibitors in breast 
cancer (53), as well as adult gliomas (54, 55). LSD1 inhibition reduced epithelial-to-
mesenchymal transition by blocking the SNAG-domain association of SLUG with LSD1 
(56). Stem cell factor SOX2 was seen to be a factor of sensitivity to LSD1 inhibition in 
cancer (57). LSD1 and SOX2 were implicated in glioblastoma development by an 
LSD1-MYC-SOX2 axis (58). The oncogenic fusion proteins EWS/FLI and EWS/ERG in 
Ewing sarcoma drive transcriptional programs that can be suppressed with LSD1 
inhibition (59, 60). LSD1 was found to be a key modulator of tumor progression in 
medulloblastoma (by its GFI1 interactions) (61) and small cell lung cancer (by its 
repression of NOTCH pathway) (62).  
Therapeutic targeting of LSD1 
LSD1 inhibitor development 
LSD1 inhibitors have been designed in many permutations, with the most 
common being relatively simple small molecules targeted to the catalytic site of LSD1 
(63). Other forms can include complex molecules (64), natural products (65, 66), and 
protein mimetics (67, 68), but these will not be expanded upon as they have not 
progressed into detailed pre-clinical studies or clinical trials.  
The earliest discovered LSD1 inhibitor was tranylcypromine, also called Parnate, 
2-PCPA, or TCP, a monoamine-oxidase inhibitor commonly prescribed as a psychiatric 
medication (69). The potency and selectivity of TCP for LSD1 versus monoamine-
oxidases A (MAOA) and B (MAOB) is poor, with TCP being >10X more selective for 
MAOs versus LSD1 and with a poor inhibitory constant (Ki) for LSD1 of several hundred 
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micromolar (µM) (70). As such, TCP must be dosed in the millimolar (mM) range to 
achieve desired effects of blocking LSD1 binding to H3 tails or other targets when used 
in cell culture (Fig 2). Derivatives of TCP with greater selectivity started to appear in 
press in 2010 (70), and were followed by a TCP derivative with hypothesized brain-
penetrant capabilities in 2012 (71). Also published that year, TCP and related 
compounds showed in vivo activity against leukemia xenografts, either as a potent TCP-
derived single agent (36) or TCP in combination with all-trans retinoic acid (ATRA) (37). 
Interestingly, the single agent TCP-derivatives produced thrombocytopenia and anemia 
in mice (36), foreshadowing publications to come in 2012/2013 (27, 28) that defined the 
role of LSD1 in hematopoiesis. In 2015, pharmaceutical company GlaxoSmithKline 
(GSK) published their potent catalytic LSD1 inhibitor, GSK LSD1 and its in vivo 
counterpart GSK2879552, showing activity in small-cell lung cancer (SCLC) and acute 
myeloid leukemia (AML) (72) (Fig 2). 
A new biochemical mechanism of LSD1 inhibition was discovered in 2013, when 
the benzohydrazide compound 12 was published, which would later become known as 
HCI-2509 or SP-2509 (73). Excellent potency (Ki = 31nM) and selectivity over MAOs 
was demonstrated as well as preliminary in vitro activity against cell lines (Fig 2). The 
following year, SP-2509 was shown to be effective in vitro and in mouse models when 
combined with HDAC inhibitors against AML (39), and as a single agent for Ewing 
sarcoma (60, 74), endometrial carcinoma (75), neuroblastoma (76), and prostate cancer 
(77). Fiskus et al found that SP-2509 can block the association of LSD1 with its complex 
member CoREST, suggesting an allosteric binding mechanism that may generate 
biological effects beyond catalytic inhibition. Developed resistance to SP-2509 does not 
12 
 
involve mutations in LSD1 but does result in decreased CoREST expression, 
suggesting CoREST is at least partially required for SP-2509 efficacy (78). 
Computational docking confirmed the allosteric binding mechanism of SP-2509, 
displaying binding of the compound at a rotational interface between the amine oxidase 
domain and the tower domain (79). These authors also found that SP-2509 causes 
LSD1 protein instability and blocks LSD1 interactions with zinc-finger 217 (ZNF217), 
which were shown to be critical to the anti-tumor effect in prostate cancer. Notably, use 
of potent catalytic inhibitors did not recapitulate these effects (79). Others have noted 
the possibility of off-target effects of SP-2509 through biochemical screens (80) and 







Fig 2. Structures and properties of LSD1 inhibitors used in dissertation. Information 
includes originating intellectual property owner, name of compound, mechanism of 
action, and inhibition constants (Ki) for LSD1 and related monoamine oxidases. Red 
boxes highlight common TCP-backbone of GSK LSD1 and RN-1. Clinical trial 
information is provided for SP-2577 (seclidemstat), current as of August 2020.  
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Several of the above agents have moved into clinical trials, mostly for 
hematological malignancies or defects, but also a handful in solid tumors (82). A potent 
catalytic inhibitor from Spain, ORY-1001, shows promising efficacy in an AML trial (83). 
TCP is in trials for AML as well, though already FDA-approved as a psychiatric 
medication. Imago Bioscience’s IMG7289, another catalytic inhibitor, was recently fast-
tracked by the FDA for treatment of myelofibrosis. Other catalytic inhibitors from 
Celgene (now owned by Bristol Myers Squibb, BMS-90011) and Incyte (INCB059872) 
are in trials for lymphoma, SCLC, sickle cell disease, and broadly for solid tumors and 
myeloproliferative diseases. GSK2879552 trials were terminated due to unacceptable 
severe adverse events (SAEs) in a SCLC trial, primarily encephalitis (84). This has not 
been seen with other LSD1 inhibitors of a similar mechanism, suggesting GSK2879552 
may have unfavorable unique properties. Notably, no clinical trials have cited dose 
limiting toxicities (DLTs) of anemia or thrombocytopenia as seen in mouse models, 
therefore early worries of a narrow therapeutic window and hematological toxicities for 
LSD1 inhibitors are abated. The clinical successor to SP-2509, Seclidemstat or SP-
2577, is also in trials for solid tumors and Ewing sarcoma. 
LSD1 as an immuno-regulator 
LSD1 was first tied to immune responses in 2012 with a report showing that 
LSD1 knockdown or inhibition in breast and liver cancer cells will upregulate 
transcription of interleukins 1, 6, and 8 (85). Several years later in 2018, the immune 
role of LSD1 was confirmed in multiple publications. CD4 T-cells in rheumatoid arthritis 
mediate disease severity, and it was discovered that LSD1 knockdown reduces CD4 
proliferation and secretion of pro-inflammatory cytokines IL-17 and IFN-gamma in 
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patient cells and an arthritis mouse model (86). It was also found that LSD1 is 
suppressed in hematopoietic cells during toxic shock, allowing pathogenic myeloid cells 
to proliferate and kill the host. The downregulation of LSD1 was driven by micro-RNAs 
(miRs) and could be reversed with anti-miRs, allowing LSD1 to suppress the toxic shock 
syndrome (87).  
Two landmark papers following that tied LSD1 to immuno-oncology and 
combinations with immunotherapy. Yang Shi’s lab, whom discovered LSD1, 
demonstrated that LSD1 knockdown induces both transcription of endogenous retroviral 
elements (ERVs) and destabilizes the RNA-induced silencing complex (RISC), which 
then leads to dsRNA accumulation and a boosted immune response driven by 
upregulated MHC and PD-L1 in breast cancer and melanoma cells (88). This was 
followed by another report in breast cancer showing that inhibition of LSD1 also raised 
PD-L1 levels, and the authors described a mechanism based on increased expression 
of chemotactic cytokines that drew in T-cells from tumor blood vessels (89). The LSD1 
complex was further implicated in normal function of regulatory T-cells by deletion of 
CoREST, where CoREST knockout mice rejected bone marrow allografts, and notably, 
rejected tumors at a higher rate (90).  
Unifying hypothesis and research plan 
LSD1 has advanced from a biochemical curiosity to a validated cancer target in 
the span of 15 years. However, much remains to be discovered about its function and 
value as a therapeutic target in multiple cancers. As I have explored above, LSD1 plays 
diverse roles in different tissue types, governed by its interacting complex members and 
the “primed” state of the epigenome, which is itself regulated by many other histone 
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modifiers. Our lab has previously explored LSD1 inhibition in adult glioblastoma and 
found that cell lines are mostly insensitive to LSD1 inhibitors, but they can sensitize 
cells to HDAC inhibition (54, 55). As part of these investigations, RNA-Seq data was 
collected from cells with LSD1 knockdown compared to wild type. From this data we 
established pathways changed by LSD1 in adult gliomas, of which we sought to 
determine if LSD1 inhibition can be combined with other therapeutic modalities, given 
the lack of cytotoxicity from LSD1 inhibition alone. 
One of our top hits from pathway analysis was immune response, which included 
several cytokines, ligands, and antigen presentation genes. At this time (2015), little 
was known about LSD1 and immune pathways, and nothing was published on this 
effect in gliomas. Using this finding as a jumping off point, I hypothesized LSD1 
inhibitors could be used as immuno-stimulatory agents in gliomas. To dissect this 
hypothesis further, I will present my findings in 3 separate chapters addressing unique 
aims of the project: 
1. LSD1 inhibition as an immuno-stimulatory strategy in glioma 
i. Verification of LSD1 immune gene signature and relevance to 
pediatric v. adult gliomas 
ii. Use of LSD1 inhibitors with unique mechanisms of action 
iii. Combination immune therapies with LSD1 inhibitors 
iv. In vivo efficacy of LSD1 + cell therapy modalities 
2. Effects of LSD1 inhibition on cytotoxic immune cells 
i. Sensitivity of NK and T-cells to LSD1 inhibition 
ii. Metabolic effects of LSD1 inhibitors 
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iii. Oxidative stress effects of LSD1 inhibitors 
iv. Function of LSD1-inhibited NK cells 
3. Immune microenvironment of pediatric high-grade gliomas (pHGGs) 
i. Computational analysis of RNA-Seq using CIBERSORT to 
determine immune infiltrate 
ii. Immunosuppression in the pHGG microenvironment 
Collectively, these chapters establish LSD1 as an epigenetic immuno-repressor 
in pediatric gliomas, as well as a potential regulator of metabolism and redox balance in 
NK cells. Examination of clinical pediatric glioma sequencing data suggests that 
immuno-stimulatory therapies need to consider tumor location and immune cell type as 
important mediators of efficacy. The use of epigenetic therapies in cancer is complex, 
due to the varied function of epigenetic targets by tissue, cell identity within the tissue, 
and epigenetic state of that cell identity. Herein I have revealed new information about 
LSD1 and its interactions with the immune system, laying the foundation for future 
cancer therapies incorporating epigenetics, immunotherapy, and energy balance, which 




Materials and Methods 
Cells and human samples 
Human pHGG cells (DIPG IV, DIPG IV-luc, VI, and XIII) were grown in tissue 
culture-treated T75 flasks (BioBasic) in Tumor Stem Medium (TSM) Base, defined as 
50% DMEM/F12 medium (Corning) and 50% Neurobasal-A medium (Invitrogen) with 
1% NEAA/HEPES/sodium pyruvate/L-glutamine (Invitrogen). Before passaging or 
plating of cells, the following growth factors were added to TSM Base by volume: 2% 
B27 (Invitrogen), 0.1% of 0.2% heparin (StemCell Technologies), 20ng/mL EGF/bFGF 
and 10ng/mL PDGF-AA/PDGF-BB (all from Shenandoah Biotechnology). DIPG IV/VI 
cells were cultured as loosely adhered monolayers (IV) or colony-forming (VI) cultures 
and DIPG XIII cells were cultured as free-floating neurospheres. DIPG IV-luc cells were 
transfected with a mKate2-Firefly luciferase cassette, sorted for mKate2 positivity, and 
confirmed for luciferase luminescence on a plate reader. LN18 adult glioblastoma and 
NHA immortalized normal human astrocyte cells were grown as adherent monolayer in 
tissue culture-treated T75 flasks in DMEM/F12 medium supplemented with 10% fetal 
bovine serum (Corning) and 1% L-glutamine.  
All adherent or neurosphere cells were detached and/or dissociated with TrypLE 
during normal passage or Accutase during analysis or use in experiments. All cell lines 
were cultured without antibiotic and monitored for mycoplasma with MycoAlert PLUS 
(Lonza) with luminescence being read on a Synergy 2 plate reader (BioTek). Cell lines 
were cultured for an average of 3 months after being thawed, with mycoplasma testing 
done after thawing and prior to freezing to maintain myco-free stock, as well as 
periodically during experimental periods. 
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PKC-HA, PHC-HA, and PKC-luc murine cells are either H3.3-WT (PHC-HA) or 
H3.3-K27M (PKC-HA and PKC-luc) on a shared TP53-flox/PDGFRA-overexpression 
background initiated in Nestin(+) neural stem cells in C57BL/6 mice as previously 
published by Oren J. Becher. PKC and PHC cells were cultured in T75 flasks in Mouse 
& Rat NeuroCult media (StemCell Technologies) with the following growth factors 
added fresh at each passage: 10% NeuroCult proliferation supplement (StemCell), 20 
ng/mL human FGF and EGF (Shenandoah), and 2 mg/mL heparin (StemCell). PKC-luc 
were transfected with luciferase by Javad Nazarian and additionally cultured in 0.5 
µg/mL puromycin to maintain stable luciferase expression. NHA cells were additionally 
cultured with 0.5 µg/mL puromycin (Sigma) and 10 µg/mL blasticidin (Cayman 
Chemical) to maintain a transformed E6/E7/TERT-overexpressing phenotype. 
Human ex vivo expanded NK cells were previously isolated from de-identified 
healthy donor peripheral blood mononuclear cells (PBMCs), expanded with feeder cells, 
and cryopreserved as stocks in liquid N2. Expanded NK cells were cultured in RPMI 
(Corning) supplemented with 10% FBS (Genesee Scientific) + 1% of each of the 
following: penicillin/streptomycin (HyClone), NEAA (Lonza), L-glutamine (Sigma), 
sodium pyruvate (Lonza), and HEPES (ThermoFisher). 100 U/mL IL-2 was added to NK 
cultures every 3 days as needed. Human T-cells were isolated from healthy donor 
PBMCs using the EasySep Human T-cell Isolation Kit, cultured in ImmunoCult-XF T-cell 
Expansion Medium, and stimulated to grow with ImmunoCult Human CD3/CD28/CD2 T 
Cell Activator supplemented with 100 U/mL IL-2 (all from StemCell Technologies). K562 
cells were cultured in the same media as NK cells but without IL-2. 
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Human cell lines DIPG, LN18, K562, and NHA cells were validated at least once 
per year by STR DNA fingerprinting using the Promega 16 High Sensitivity STR Kit 
(Catalog # DC2100). The STR profiles were compared to online search databases 
(DSMZ/ATCC/JCRB/RIKEN) of approximately 2500 known profiles; along with the MD 
Anderson Characterized Cell Line Core (CCLC) database of approximately 2600 know 
profiles. The CCLC core cannot validate mouse cells. 
Clinical datasets and bioinformatics 
The pHGG dataset published by Mackay et al was queried for a 13-gene 
signature identified from LSD1 knockdown RNA-Seq, and we performed supervised 
clustering on patients by using the expression of 8 of the 13 genes and expression of 
LSD1 (5 of the genes were not present in the dataset). With the clustering analysis, two 
distinct populations emerged with either low expression of the 8-gene signature (n = 
142) or high expression (n = 105). The expression of LSD1 is significantly correlated 
with the two subgroups with p-value at <0.0001 via unpaired T-test. Data for histone 
mutation status, anatomic location of the tumor, survival, and LSD1 expression were 
exported to Excel and GraphPad Prism for further analysis. Raw RNA-Seq from the 
dataset was input into CIBERSORT algorithm and output with the standard LM22 
matrix. Individual patients were segmented into H3-WT hemispheric tumors and H3-
K27M brainstem tumors for further analysis and matched to survival data. Midline and 
G34R/V hemispheric tumors were discarded from analysis due to lack of statistical 
power. CIBERSORT values per patient and immune cell type were classified as 




Mouse models of hemispheric pHGG and brainstem DIPG 
All experimental procedures were approved by the Institution Animal Care and 
Uses Committee (IACUC) at the University of Texas MD Anderson Cancer 
Center. NOD-SCID gamma (NSG) mice were intracranially bolted at 4 weeks of age 
and PKC-luc murine pHGG cells or DIPG IV-luc human DIPG cells were injected at 6 
weeks of age. 300,000 PKC-luc cells or 500,000 DIPG IV-luc cells were infused in 5 µL 
suspended in serum-free media without growth factors through the bolt and allowed to 
engraft for 1-2 weeks. Mice were injected 200 µL intraperitonially (IP) with vehicle (1.6% 
DMA, 5% EtOH, 45% PEG400, 48.4% PBS) or drugs resuspended in vehicle at the 
following doses: TCP (16 mg/kg), GSK LSD1 (1.6 mg/kg), and SP-2577 (16 mg/kg). 
Treatment was performed on a 4 days on/3 days off cycle to manage toxicity as 
suggested by collaborators at GSK. NK cells at a dose of 1,000,000 cells/mouse were 
infused through the cranial bolt in 5 µL suspended in serum-free RPMI weekly after 4 
days of treatment with LSD1 inhibitor. Luminescent images were captured following 
every cycle of treatment by anaesthetizing mice with 2.5% isoflurane, injecting with 3 
mg luciferin in a 200 µL subcutaneous dose, incubating for 5 mins, and imaging 
immediately on an IVIS 200 (PerkinElmer) for 1, 5, and 15 seconds. Images were 
normalized to a radiance range of either 500,000 to 10,000,000 (PKC-luc) or 50,000 to 
5,000,000 photons/sec/cm2 (DIPG IV-luc) for presentation. Total flux (photons/sec) was 
used to quantify tumor burden and plot data over time. 
C57BL/6 female mice of 8 weeks of age were anaesthetized via isoflurane at 
3.5% and foot pinch was used to confirm deep anesthesia. Using a scalpel, an incision 
was made on the top of the head to expose the skull. Mice were placed in a stereotactic 
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apparatus under anesthesia and a hole was drilled in the skull below the bregma and 
lateral to the sagittal suture at a depth of 2 mm. 500,000 PKC-HA murine DIPG cells in 
3 µL of PBS were injected to a 5 mm depth using a 10 µL Hamilton syringe at a rate of 
0.5 µL/min. After injection, the syringe was slowly retracted and the head was re-sealed 
with VetBond tissue adhesive. Mice were monitored for 1-2 hours post-surgery for 
normal walking gait and alertness. Mice were given Buprenorphine at 0.1 mg/kg via 
subcutaneous injection for the next 2 days post-surgery to alleviate pain. Tumor 
engraftment was allowed to proceed for 2 weeks, then mice began treatment by 200 µL 
intraperitoneal (IP) injection with PBS or drugs resuspended in PBS at the following 
doses: TCP (10 mg/kg) and GSK LSD1 (1 mg/kg). Treatment was performed on a 4 
days on/3 days off cycle. Mice were monitored for neurological symptoms including 
circling, head tilt, weight loss, and abnormal gait and were sacrificed if symptoms were 
severe. Brains were extracted and either flash-frozen in liquid nitrogen or fixed in 10% 
formalin solution (Sigma). Frozen brains were processed for RNA extraction using silica 
beads and sonication, while fixed brains were transferred to 70% EtOH for storage and 
subsequently processed into FFPE tissue blocks. Slide preparation and IHC was 
performed by the MD Anderson Smithville Pathology Core who confirmed tumor 
engraftment with core-validated Ki67 and user-provided HA-Tag (Cell Signaling) 
antibodies. Immunofluorescence staining was performed by the UT MD Anderson Flow 
Cytometry and Cell Imaging Core (Science Park, Smithville TX) with funding support 
provided by the CPRIT core facility grant RP170628. Slides were stained using NK1.1 
(BioLegend) and CD3 (Abcam) primary antibodies and AlexaFluor conjugated 
secondaries (ThermoFisher) combined with DAPI stain. Laser scanning confocal 
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microscopy was performed using a Zeiss LSM880 and 20X (0.8 NA) Plan/Apo objective 
with a pinhole aperture of 1-1.5 AU. Tile scans of the injected area were used to select 
tumor core, margin and adjacent stromal regions. For quantifications of infiltrating 
immune cells multispectral images were acquired at 2X zoom with a 212 mm2 field of 
view and quantified by eye. 
Cellular thermal shift assay (CETSA) 
At least 1 x 106 NHA or DIPG cells were plated in T75 flasks for each 
experimental condition and treated with LSD1 inhibitors for 1 hour. Cells were then 
harvested with TrypLE, washed in PBS, and resuspended in 200 µL cold CETSA wash 
buffer (defined as PBS with protease inhibitor cocktail added). 50 µL of each 
experimental condition were aliquoted into PCR strip tubes to make the melt curve. For 
LSD1, the temperatures were 42, 44, 48, and 52 C; this will vary for each protein being 
interrogated. Each set of aliquots was heated in a gradient thermocycler (BIO-RAD) for 
3 mins then cooled to 25C indefinitely. Strip tubes were immediately freeze/thawed in 
liquid nitrogen for 3 cycles to induce cell lysis. Lysates were spun down in a 
microcentrifuge at 12,000 RPM for 20 mins at 4C. Cleared lysates were either frozen at 
-80C or 15 µL was immediately loaded onto polyacrylamide gels for Western blot as 
described. 
NK and T-cell cytotoxicity co-culture 
For DIPG cell killing assays, DIPG target cells were grown under treatment 
conditions for defined times and doses, then harvested with Accutase and stained with 
calcein AM at 4 µM in NK cell media for 60 mins at 37C. Calcein AM-stained cells were 
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counted and plated in 96-well round bottom plates (Corning) at 50,000 cells/well, then 
NK or T-cells were added at defined effector-to-target ratios. 1% Triton-X (max lysis) 
and media only (background lysis) of target cells alone were included for each treatment 
condition. Plates were spun down at 100 x g for 1 min to initiate cell contact and then 
incubated for 4 hours at 37C. Following incubation, wells were mixed gently and plates 
then spun down at 100 x g for 5 mins, and 100 µL supernatant media was moved to 
clear-bottom, white-walled 96-well plates. Fluorescence was read at 485nm 
excitation/530nm emission on a Spectramax Gemini EM plate reader (Molecular 
Devices) with bottom read setting. Percent specific lysis was calculated by the formula: 
specific lysis = ((experimental release - background release) / (maximum release – 
background release)) * 100. 
For LSD1 inhibitor treatment of NK cells, effector NK cells were pre-treated for 
48h with LSD1 inhibitors (+ or – 2.5mM GSHee), counted on a ViCell XR analyzer, 
washed in PBS, and resuspended at 2 x 106 live cells/mL in supplemented RPMI. Cells 
were plated in a round-bottom 96-well plate in 100µL/well and serially diluted once to 
make 10:1 and 5:1 effector-to-target ratios in triplicate. Background wells were loaded 
with 100µL media only and maximum release wells were loaded with 100µL 2% Triton-
X in media. K562 cells were counted and resuspended at 1 x 106 live cells/mL and 
incubated with 5µM calcein AM for 1hr at 37C with mixing every 10 mins. After calcein 
AM loading, cells were washed in PBS, counted and resuspended at 2 x 105 live 
cells/mL and 100µL was added to each well of the plate. After centrifugation at 100 x g 
for 2 mins, the plate was incubated at 37C for 4hrs. After incubation, wells were gently 
mixed to distribute released calcein AM and the plate was centrifuged at 400 x g for 2 
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mins. 100µL of supernatant was transferred to a black opaque flat-bottom 96-well plate 
(Nunc) and fluorescence was read on a Synergy 2 plate reader (BioTek) with 485nm 
excitation/528nm emission filter set. Percent specific lysis was calculated by the 
formula: specific lysis = ((experimental release - background release) / (maximum 
release – background release)) * 100. 
Cellular metabolism assays 
NK and T-cells were pre-treated with indicated compounds for 48h, counted on a 
ViCell XR analyzer (Beckman Coulter), washed in PBS, and resuspended in Seahorse 
XF base DMEM (Agilent) supplemented with 10mM glucose (Sigma), 2mM L-glutamine, 
and 1mM sodium pyruvate. CellTak (Corning) was used to adhere 300,000 live cells per 
well in a Seahorse 96-well plate (Agilent) following manufacturer protocol. XF Mito 
Stress Test kit (Agilent) was used with 1µM oligomycin, 0.5µM FCCP, and 0.5µM 
rotenone/antimycin A with the standard injection protocol. Analysis was performed on a 
Seahorse XFe96 analyzer (Agilent) using Wave 2.6.1 software. 
Chemicals and antibodies 
The compounds tranylcypromine (TCP) (Enzo Biosciences), GSK LSD1, RN-1 
(Cayman Chemical), SP-2509 (EMD Millipore), lapatinib, dasatinib, imatinib, gefitinib 
(LC Labs), idelalisib, and alpelisib (BYL719) (Cayman Chemical) were purchased from 
the indicated vendors. SP-2577 was provided as both a free base formulation (in vitro) 
and mesylate formulation (in vivo) by Salarius Pharmaceuticals. Cyst(e)inase was 
provided by John Digiovanni, Ph.D. and the University of Texas at Austin. TCP was 
suspended in phosphate-buffered saline solution (PBS), while all other drugs were 
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suspended in dimethyl sulfoxide (DMSO) and aliquoted for storage at -20C. AlamarBlue 
was made from 2 g resazurin sodium salt (Sigma) resuspended in 500mL sterile PBS 
and stored at 4C as a 100x solution. GelGreen (Biotium) was stored in the dark at room 
temperature. D-Luciferin (GoldBio) was resuspended in sterile PBS and stored in 
aliquots at -20C. Glutathione ethyl ester (GSHee) (Cayman Chemical) was suspended 
in water and aliquoted at –20C. Trolox (Cayman Chemical) and mitoquinol (MQ) 
(Cayman Chemical) were suspended in DMSO and aliquoted at –20C. SKQ1 (Cayman 
Chemical) was provided in a 1:1 EtOH:H2O solution and diluted in cell culture media for 
experiments. Calcein AM (Cayman Chemical) was resuspended in DMSO and aliquoted 
at –20C. 
Antibodies for LSD1 (Abcam), β-Actin (Sigma), H3K4me2 (Cell Signaling), 
CoREST (MilliporeSigma), GFI1 (Santa Cruz), SLAMF7 PE (Biolegend), MICB APC 
(R&D Systems), CD3 FITC (BD Biosciences), CD56 PE (BD Biosciences), CD16 PE-
Cy7 (ThermoFisher), and NKG2D APC (ThermoFisher), and ULBP-4 Alexa 488 (R&D 
Systems) were used at manufacturer recommended dilutions for western blot or flow 
cytometry. Isotype antibodies matched to the species, class, and fluorophore were used 
in flow cytometry experiments.  
Drug screening 
All compounds were screened for efficacy against cells using 96-well flat-bottom 
plates (BioBasic) and AlamarBlue fluorescence as readout for live cell number or 
GelGreen fluorescence as readout for cell death. Cells were plated as single cell 
suspension at 2,000 cells/well (LN18/NHA/DIPG IV), 10,000 cells/well (DIPG VI/XIII), or 
20,000 cells/well (NK/T-cells) in 150µL of medium and were allowed to adhere overnight 
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(LN18/NHA/DIPG IV) or were grown for 3-4 days until colonies (DIPG VI) or 
neurospheres (DIPG XIII) formed. Only the inner 60 wells of the plate were used; wells 
on the perimeter were filled with 200 µL PBS to control for edge effect. For treatment, 
drugs were diluted in medium to a 6X working stock, and 30 µL of the stock was added 
to the 150 µL of medium in each well for a total of 180 µL/well. For live cell counts, 
plates were incubated for 4 days, and 18 µL AlamarBlue was added at the end of day 4. 
On day 5, fluorescence was read at 540nm excitation/600nm emission on a Synergy 2 
plate reader with the bottom read setting. For cell death count, cells were plated in 
white-walled flat clear-bottomed 96-well plates (Grenier) and grown as above. GelGreen 
was added during drug treatment to a final concentration of 2X, and fluorescence was 
read at 485nm excitation/528nm emission as above. Using GraphPad Prism, dose 
responses were transformed to log scale and normalized to DMSO controls; a sigmoidal 
curve was plotted to calculate the median inhibitory concentration (IC50). 
Trypan blue, apoptosis, and cell cycle assays 
Cells were harvested with TrypLE, spun down, and resuspended in 800 µL PBS. 
500 µL of cells were analyzed for viability by TrypanBlue exclusion on a ViCell XR 
(BeckmanCoulter). The remaining 300 µL was fixed by adding 700 µL dropwise of ice 
cold 100% ethanol and storing at -20C. After a minimum of 24 hours, fixed cells were 
spun down, washed in PBS, and resuspended in a mixture of 300 µL PBS with 37.5 µM 
propidium iodide and 100 µg/mL of Ribonuclease A and incubated for 30 mins at RT in 
the dark. Cells were immediately analyzed on a Fortessa flow cytometer and 




Plate reader-based glutathione detection assay 
After desired incubations, cells were harvested with TrypLE and centrifuged at 
1700 RPM for 3 mins @ RT. Each experimental condition was resuspended in 1 mL 
PBS and 2 µL of a 50µM monochlorobimane (mBCL) solution (mBCL in acetonitrile) 
was added to each sample. 2 µL acetonitrile alone was added to the unstained control. 
Samples were vortexed and incubated at 37C for 30 mins. 50 μL of trichloroacetic acid 
was added and samples were spun for 5 min at 10,000 RPM @ RT. 1 mL of the 
resulting supernatant was added to a glass tube containing 1 mL dichloromethane. 
Glass tubes were vortexed and centrifuged for 2 min at 3,500 RPM @ RT. For each 
sample, 200 μL of the top aqueous layer was plated in duplicate wells in a black opaque 
96-well plate. Fluorescence was read on a BioTek Synergy 2 plate reader using the 
360nm excitation/460nm emission filter set.  
RNA isolation and RT-qPCR 
RNA was isolated using the RNeasy kit (QIAGEN) following manufacturer 
protocol. RNA was quantified on a Nanodrop 1000 spectrophotometer (ThermoFisher) 
and 500-1000 µg of RNA was reverse transcribed into 20 µL cDNA using the iScript 
cDNA synthesis kit (BIO-RAD). cDNA was diluted in template buffer (Biotium) by 2X, 
and 1 µL cDNA was plated in duplicate or triplicate on a 96-well qPCR plate (USA 
Scientific) mixed with 10 µL 2X Forget-Me-Not EvaGreen qPCR Master Mix, 8 µL 
nuclease-free water, and 1 µL of a 10 µM mix of forward and reverse primers for genes 
of interest. Primers are listed in supplementary table 1. Assay was run on a LightCycler 
96 instrument (Roche) using Biotium protocol and analyzed with LC96 software (Roche) 
to confirm amplification and single melt peaks. Ct values were exported and analyzed in 
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Excel using the 2-ΔΔCT method compared to DMSO controls. Fold changes were plotted 
in GraphPad Prism using multiple biological replicates. 
Flow cytometry 
Cells were harvested with Accutase after being treated for indicated time points 
and doses and washed with PBS in 5mL FACS tubes. Ghost Dyes Red 780 and Violet 
450 (Tonbo Biosciences) were diluted 1:9 (Red 780) and 1:4 (Violet 450) for use in 
50uL PBS/sample to stain cells for 10 mins at RT before addition of antibodies or other 
dyes. 50 µL of antibody mixture diluted in 2% BSA in PBS was added using the 
manufacturer recommended dilutions of 5 µL/1 x 106 cells and incubated at 4C for 25 
mins. Monochlorobimane (mBCL) (Sigma) was used at 20µM in PBS to stain cells for 
20 mins at 37C and acquired in the AmCyan channel. MitoSOX Red (ThermoFisher) 
was used at 1µM in PBS to stain cells for 20 mins at 37C and acquired in the PE 
channel. MitoTracker Deep Red (ThermoFisher) was used at 250nM in PBS to stain 
cells for 20 mins at 37C and acquired in the APC channel. Cells were washed with 
FACS buffer (PBS + 2% BSA + 0.01% sodium azide) and resuspended in 300µL FACS 
buffer for acquisition on a Fortessa flow cytometer (BD Biosciences) with 
405nm/488nm/640nm laser setup. Compensation was calculated using FACSDiva 
software and UltraComp beads (ThermoFisher) stained with indicated antibodies. Data 
was analyzed with FlowJo 10.6 (FlowJo, LLC) gating on live cells and measuring MFI 




NHA and DIPG cells were transfected with a scramble (control) or LSD1 siRNA 
cocktail (Santa Cruz Biotechnology) using Lipofectamine RNAiMAX (ThermoFisher 
Scientific) with the standard protocol for 6-well plates. Cells were incubated for 48 hours 
then harvested for lysates and RNA. Knockdown was confirmed via western blot. DIPG 
IV were subjected to sequential transfection every 24h before harvesting at 48h using 
100nM of siRNA. NHA were subjected to one transfection at 10nM siRNA for harvesting 
at 48h. 
Western blotting 
 At least 1 x 106 cells were harvested with TrypLE and washed once with PBS, 
followed by lysis with RIPA buffer for at least 1 hour rotating at 4C. Lysates were spun 
at 12,000 RPM for 20 minutes at 4C to pellet debris. Protein content was measured via 
Bradford assay (BIO-RAD) with bovine serum albumin (BSA) diluted in PBS used to 
establish the standard curve. Absorbance was measured at 750nm on a SpectraMax 
Plus 384 plate reader (Molecular Devices). Equal amounts of protein were loaded on a 
polyacrylamide gel for sodium dodecyl sulfate-gel electrophoresis and run at 100V for 2 
hours. Proteins were transferred to polyvinylidene fluoride (PVDF) membranes via wet 
transfer at 100V for 1 hour. Membranes were blocked with 1% fish gelatin for 1 hour at 
room temperature. Antibodies were incubated overnight at 4C with gentle agitation. The 
next day, the membranes were washed with Tris-buffered saline solution containing 
Tween (TBST) and incubated with horseradish peroxidase–conjugated (HRP) 
secondary antibody (Cell Signaling Technology). Proteins were visualized by SignalFire 
ECL Reagent (Cell Signaling Technology) for 1 minute and imaged on a ChemiDoc 
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Touch (BIO-RAD). Images were evaluated with Image Lab software (BIO-RAD) and 
protein expression quantified with ImageJ (US National Institutes of Health). 
Statistical analysis 
GraphPad Prism 8.4.2 was used for all graphing and statistical analysis. Patient 
data was analyzed using Wilcoxon and Log-Rank tests for survival. RT-qPCR data was 
analyzed using ANOVA correcting for multiple comparisons by use of the False 
Discovery Rate (FDR) approach. Discovery was determined using the Two-stage linear 
step-up procedure of Benjamini, Krieger and Yekutieli, with Q = 1%. All other data was 
analyzed using T-tests correcting for multiple comparisons using the same FDR 
approach and cutoff. Comparisons were made to DMSO controls where appropriate or 




SLAMF7 Forward AAGGGGAATGGCTGCTTTTG 
SLAMF7 Reverse CTCAATCCCATTCTTGCCCAAC 
GPR65 Forward CATCCCACCTAGGTCTCCCA 
GPR65 Reverse CACATCACTTCCCCCTCACC 
LCP1 Forward GCAGTTTGTCACAGCCACAG 
LCP1 Reverse TCATTGACCTTCTGGCCACC 
RAET1E Forward TGTGAAGCGCAGGTCTTCTT 
RAET1E Reverse AACAGGATGAATGCCCCCAG 
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4-1BB Forward TGCTTGTGAATGGGACGAAG 
4-1BB Reverse ACGTCAGCGCAAGAAAGAAG 
MICB Forward ATGAGGTGTTTGCTGCTCTG 
MICB Reverse TTTGCCCACATCCTGCATTC 
KYNU Forward TCAGTGGAGACCATCGACAG 
KYNU Reverse GCATTTGAGTTCAGCCGCAA 
ARHGDIB Forward GCCCAGGGTTTCCTCTTCAA 
ARHGDIB Reverse GGGTGCCTCTGTCTCTCAAC 
CTSS Forward TCCTACCCTGGATCACCACT 
CTSS Reverse TTCTTCACTGGTCATGTCTCC 
IL20RB Forward GCTGATGCAACATCTGGGTTT 
IL20RB Reverse TGCATATGTTGGAGCTGAGG 
LAT2 Forward TTGCAACAGTTCTTGGAAACCC 
LAT2 Reverse GTTGCCTCTTGTGATGCGTG 
IL18 Forward AAGATGGCTGCTGAACCAGT 
IL18 Reverse GAGGCCGATTTCCTTGGTCA 
OAS2 Forward AGCTCTTTACTTTCCCCTTGGTT 
OAS2 Reverse GGAAACAGACAGGACGTGGA 
PPIA Forward CCCACCGTGTTCTTCGACATT 
PPIA Reverse GGACCCGTATGCTTTAGGATGA 
HPRT1 Forward CCTGGCGTCGTGATTAGTGAT 
HPRT1 Reverse AGACGTTCAGTCCTGTCCATAA 
ACTB Forward CTGTGGCATCCACGAAACTA 
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Background 
Pediatric high-grade gliomas (pHGGs) are pathologically diverse yet uniformly 
highly malignant central nervous system (CNS) cancers, with 5-year survival rates of 
<10% post-diagnosis. Surgery is often not possible due to tumor diffusion and the 
sensitive midline brain structure, which control crucial motor functions such as breathing 
and heartbeat. Radiotherapy is the standard of care, but survival benefits are slim with 
high risks of side effects and decreased quality of life during and after treatment (91). 
Immunotherapeutic approaches have had limited success due to the low mutational 
burden and immunosuppressive microenvironment of pediatric brain tumors, such that 
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adaptive immune interventions including checkpoint blockade are ineffective (92). 
Recent efforts to molecularly profile pHGGs have discovered conserved genomic 
mutations unique to the pediatric age range and anatomical locations (93). In particular, 
mutations in histone encoding genes (H3F3A, HIST1H3B) resulting in amino acid 
substitution of the epigenetically critical lysine residue (H3-K27M) are thought to drive 
early development of these tumors in multipotent CNS cells (94). As such, the World 
Health Organization (WHO) now recognizes these K27M tumors as separate entities in 
the glioma classification (95). 
The K27M histone mutations present a therapeutic opportunity for the use of 
epigenetic regulating drugs, in particular those that target chromatin-modifying proteins. 
Multiple publications have explored this idea, using inhibitors of histone deacetylases 
(HDACs) (96), demethylases (JMJD3/UTX) (97), methyltransferases (EZH2) (98), and 
chromatin readers (BET) (99) to demonstrate tumor regression in pre-clinical models. 
Clinically-translatable compounds exist to target all of these and indeed an ongoing 
clinical trial is testing the HDAC inhibitor panobinostat as a monotherapy 
(NCT02717455) (100). However, other chromatin modifiers have yet to be explored as 
therapeutic targets, and there is limited investigation into how the gene expression 
changes generated by these drugs can be used to augment pre-existing therapies.  
The histone demethylase LSD1 removes mono- and di-methyl marks from H3K4 
and H3K9 and shares structural homology with monoamine oxidases (MAOs). LSD1 is 
targeted by several drugs (63) and has thus far been therapeutically investigated in 
cancers including acute myeloid leukemia (83), sarcoma (60), and neuroblastoma (76). 
LSD1 inhibition has been shown to have an enticing therapeutic window that is selective 
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for cancer cells, in part through its disruption of oncogenic and onco-maintenance 
transcriptional programs (48, 72). Furthermore, the H3K4me1 histone mark regulated by 
LSD1 was seen to be enriched in intergenic regions of pHGG cells (99), suggesting that 
LSD1 may control access to enhancers of genes important in pHGG pathology. LSD1 
inhibitors can functionally target either the catalytic domain that mediates demethylation 
(47), or the scaffolding tower domain that interfaces with other proteins in epigenetic 
complexes (78), and it is currently unknown what phenotype these disparate inhibitors 
would produce in pHGG. Given the highly disrupted yet therapeutically sensitive 
epigenome of pHGGs, we sought to explore in this study whether LSD1 inhibition could 
be both cytotoxic to pHGG and generate transcriptional changes that would inform 
combination therapies.  
Our group previously published a report on use of a combination therapy of LSD1 
and HDAC inhibition to synergistically induce cell death in adult glioblastoma cell lines 
and patient-derived glial stem cells (54). In a follow-up study, we used RNA-Seq to 
explore how the HDAC/LSD1 inhibitor combination therapy produced gene changes in 
the p53 family members p63 and p73 (55). In our current study, we identify an LSD1-
induced immunogenic gene signature conserved in pHGG patients (101) that predicts 
longer survival. We further show that LSD1 inhibition is selectively cytotoxic to DIPG 
cells, and inhibitor-based induction of this gene signature augments innate immune 
reactivity against DIPG by boosting natural killer (NK) cell immunotherapy response in 




We previously performed RNA-Seq (55) on LN18 adult glioblastoma cells when 
LSD1 was knocked down with shRNA in order to explore the mechanism of their 
sensitivity to dual LSD1 and HDAC inhibition. In the LSD1 shRNA group alone, we 
applied a 1.5-fold change filter and analyzed the remaining genes with DAVID pathway 
analysis (Fig 3A). The 3rd-most significantly changed pathway was “immune response”, 
with 24 genes upregulated and downregulated by LSD1 knockdown compared to a 
scramble control. We sought to validate these gene changes in LN18 cells, and 
replicated LSD1 knockdown in the cells and confirmed knockdown with western blot. 
Expression of the 13 most upregulated genes was measured with RT-qPCR and we 
observed a significant increase (ANOVA, p<0.0001) in the gene expression signature 
with LSD1 knockdown (Fig 3B). This confirmed our RNA-Seq data that LSD1 controls 
expression of these genes in a glioblastoma cell line. Furthermore, this gene signature 
matches treatment of LN18 with the established LSD1 inhibitor tranylcypromine (TCP) 
(Fig 3B), and TCP treatment of LN18 compared with DIPG cells was non-significant (Fig 
3C) indicating concordance of these upregulated immune genes between pediatric and 
adult glioma in vitro models.  
To determine the significance of this signature to patient treatment, we next 
proceeded to probe a dataset of 247 pediatric high-grade glioma patients (Fig 3D). 
Expression of LSD1 was significantly lower in patients with high expression of our 
identified gene signature panel, suggesting that LSD1 may influence expression of 
these genes in pHGG patients (Fig 3E). We found our gene signature of immune 
response genes could predict significantly improved 5-year survival in all tumors (Fig 
3F). The overall benefit was driven by K27M midline (thalamus, cerebellum, spinal cord, 
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ventricles; n = 23) and WT hemispheric (cerebral hemispheres; n = 57) tumors; notably, 
this survival benefit did not extend to K27M brainstem (pons, midbrain, medulla; n = 49) 
tumors, and we lacked statistical power in WT brainstem (n = 9) and WT midline (n = 
14) tumor samples to make strong conclusions (Fig 3F).  
Further verification of LSD1’s ability to suppress these immune genes in pHGG 
patients is seen when a linear regression is plotted comparing LSD1 with individual 
genes from the gene signature. Because this data set filtered out low expressing genes, 
I could not perform this comparison for 5/13 genes from the signature (SLAMF7, MICB, 
RAET1E, ARHGDIB, and LAT2). The remaining 8 genes show consistent negative 
correlations with LSD1, indicating that higher expression of LSD1 may suppress 
expression of these genes. Notably, the correlation was weaker and non-significant for 
4-1BB, OAS2, and IL20RB, while Spearman and Pearson correlations were highly 
significant for the remaining 5 genes (Fig 4A). I also examined LSD1 as a solo marker 
of patient survival, comparing patient prognosis of the top 20% and bottom 20% 
expressors of LSD1, first in all pHGG patients and then segmenting by WT hemispheric 
and K27M brainstem. The remaining subsets did not have a large enough sample size 
to perform this analysis and generate valid insights. In all pHGG patients, LSD1 
expression does not predict survival benefit, and this also holds true for WT hemispheric 
pHGGs. Interestingly, K27M brainstem patients live significantly longer when LSD1 
expression is low (Fig 4B), suggesting that LSD1 may play a role in tumor growth in 
brainstem patients, but the LSD1 immune-signature survival benefits are only seen in 








Fig 3. LSD1 immunogenic signature is predictive of survival benefit in pediatric high-
grade glioma patients. (A) RNA-Seq pathway analysis performed in LSD1 shRNA 
transduced LN18 cells. Immune response genes and associated fold changes are 
shown. (B) RT-qPCR of immune gene signature in LN18 cells with LSD1 shRNA or 
1mM TCP treatment for 24h analyzed by one-way ANOVA with FDR correction. (C) RT-
qPCR of immune gene signature in LN18, DIPG IV, and DIPG VI after 1mM TCP 
treatment for 24h analyzed by one-way ANOVA with FDR correction. (D) Heat map of 
pHGG patient exome data probed for LSD1 immune gene signature. (E) LSD1 
expression of patients expressing high and low levels of gene signature analyzed by 
unpaired T-test. (F) Survival curves of pHGG patient data subdivided by histone 
mutation and tumor location and analyzed by Log-Rank or Wilcoxon tests. * = p < 0.05, 
** = p < 0.01, **** = p < 0.0001, ns = not significant. At least 3 biological replicates were 







Fig 4. LSD1 expression significantly correlates with immune gene expression and 
patient survival in pHGG dataset. (A) Gene expression from pHGG patients plotted as 
LSD1 (x-axis) versus labeled immune genes (y-axis), with R-squared, slope equation, 
and correlation p-values presented for each comparison. N = 247 tumors with RNA-Seq 
data. (B) Survival curves of pHGG patients segmented by tumor location and LSD1 
expression level. * = p < 0.05 by Wilcoxon and Log-Rank tests.  
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In order to explore the potential of therapeutically triggering this gene signature, 
we profiled the potency of 3 irreversible catalytic LSD1 inhibitors (tranylcypromine, also 
known as TCP, GSK LSD1, and RN-1) and 2 reversible scaffolding LSD1 inhibitors (SP-
2509 and SP-2577). As we have previously published, LSD1 inhibition alone in adult 
glioblastoma cells does not potently reduce viability (54, 55). In pHGG cells, the same 
inhibitors display much greater potency that correlates with their specificity and 
sensitivity for inhibition of LSD1 over the related proteins LSD2, MAO-A, and MAO-B. 
We observed highly similar IC50s between the unique DIPG cell types for each LSD1 
inhibitor tested (Fig 5 A-C). While AlamarBlue screening is a sensitive assay for cell 
proliferation, it cannot determine if drugs are cytostatic or cytotoxic due to its reliance on 
metabolic activity. Therefore, we used trypan blue (membrane integrity) and PI stain 
(DNA fragmentation) assays to quantify cell death at the IC50s observed with 
AlamarBlue (TCP: ~1.5mM, GSK LSD1: ~400µM, RN-1: ~60µM, SP-2509/2577: 
~13µM). Cell death was selectively induced in DIPG cells over normal human 
astrocytes (NHA) beginning at 3 days post-treatment (Fig 5D). For neurosphere-forming 
DIPG XIII cells, we adapted another high-throughput technique to quantify cell death by 
use of the DNA-binding dye GelGreen and observed the same effects. In order to 
ascertain in vivo efficacy, luciferase labeled murine pHGG PKC-luc cells were implanted 
intracranially into NSG mice which were treated intraperitoneally (i.p.) four times weekly 
with vehicle, LSD1 catalytic (TCP and GSK LSD1), or LSD1 scaffolding (SP-2577) 
inhibitors.  Non-invasive imaging showed reduction of tumor burden in mice treated with 
GSK LSD1 (Fig 5E-F) but not TCP or SP-2577. GSK LSD1 provides an initial survival 
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benefit over vehicle control but this is not maintained (Fig 5G), likely due to adaptive 








Fig 5. LSD1 inhibitors are growth inhibitory in vitro and in vivo and induce selective cell 
death in DIPG cells. (A) Dose response curves of LSD1 inhibitors in DIPG IV, (B) DIPG 
VI, (C) DIPG XIII, and (D) NHA measured using AlamarBlue after 120h treatment. Cell 
viability after 72 and 96h measured using trypan blue cell exclusion and analyzed by T-
test comparing with DMSO control using FDR correction. DNA fragmentation measured 
using propidium iodide on flow cytometry analyzed by T-test comparing with DMSO 
control using FDR correction. Cell death of DIPG XIII (C) measured using GelGreen 
fluorescent intensity in 96-well plate reader and analyzed by T-test comparing with 
DMSO control using FDR correction. (E) Images of orthotopic tumor luminescence in an 
NSG pHGG hemispheric mouse model. Mice are shown after 2 weeks of treatment and 
4 weeks after tumor implantation. (F) Quantification of tumor burden shown in (E). 
Vehicle group compared to GSK LSD1 group via T-test with FDR correction. (G) 
Survival curves of NSG pHGG mice at 100 days and 150 days. * = p < 0.05. At least 3 




 We further profiled the on-target binding of our LSD1 inhibitor suite through 
assessment of the H3K4me2 mark and by use of the cellular thermal shift assay 
(CETSA). Western blotting in DIPG IV and VI lines treated with LSD1 inhibitors showed 
increased expression of the H3K4me2 mark consistently by GSK LSD1 in both lines 
(Fig. 6A). Using CETSA, we could determine if LSD1 is bound by various LSD1 
inhibitors in DIPG and NHA cells by heating live cells under treatment with candidate 
compounds and interrogating the thermostability of the target protein via western blot 
(Fig 6B). It was observed that all catalytic LSD1 inhibitors could bind LSD1 in all cell 
types, while results were less consistent with the scaffolding LSD1 inhibitor compounds 
(Fig 6C). We hypothesized the dose of SP-2509 and SP-2577 may be too low to 
thermostabilize LSD1, so we conducted dose response CETSAs with TCP as a positive 
control. We found a ~50% increase in binding in DIPG VI by raising doses of SP-2509, 
but no increase in binding above DMSO control with higher doses of SP-2577 in either 
DIPG cell type (Fig 6D). Given that we dosed up to 100 µM for the dose response 
CETSA, which is almost 10X the IC50 of the scaffolding inhibitors in DIPG cells, either 
the CETSA assay cannot capture the protein complex-disruption properties of the 
scaffolding compounds or there exists off-target effects, of which there is published data 








Fig 6. LSD1 inhibitors alter histone methylation levels and thermostabilize LSD1 in 
DIPG and NHA cells. (A) Western blots of DIPG IV and VI cells treated with LSD1 
inhibitors for 24h and probed for H3K4me2 expression. (B) Representative western blot 
of CETSA probing LSD1 thermostability in DIPG VI cells. (C) Protein melt curves for 
LSD1 in different cell types. Each data point was normalized to beta-actin level and 
further normalized to 42C data point for each experimental condition. (D) Dose 
response CETSA for scaffolding inhibitors SP-2509/2577. LSD1 was destabilized at 
48C for all doses and DMSO control was set as 0% stability and 1mM TCP was set as 
100% stability. At least 3 biological replicates were used for all experiments. Error bars 




With sensitivity and on-target activity of LSD1 inhibition in DIPG established, we 
next treated cells with sub-cytotoxic doses of LSD1 inhibitors for 24 h and isolated RNA 
to measure expression of our immune gene signature. DIPG cells display a significant 
upregulation of the signature under treatment with irreversible catalytic LSD1 inhibitors, 
but no significant changes when treated with reversible scaffolding LSD1 inhibitors SP-
2509 and its clinical successor SP-2577 (Seclidemstat). This gene signature was also 
selective for DIPG, as the same treatment did not induce upregulation NHA cells (Fig 
7A-B). We confirmed this selectivity by using LSD1 siRNA in DIPG IV and NHA cells, 
where we observed upregulation in DIPG but not NHA, at comparable levels of LSD1 
knockdown (Fig 8). Several genes in the signature correspond to immune signaling 
receptors, so we next profiled protein expression of 3 innate immune receptors known 
to play roles in NK cell signaling (SLAMF7, MICB, and ULBP-4). Using flow cytometry, 
we found DIPG cells display differing baseline levels of these receptors, perhaps due to 
their mutational differences in histone alleles (H3.1 v. H3.3). Overall however, we could 








Fig 7. Irreversible catalytic LSD1 inhibitors selectively generate immunogenic signature 
in DIPG cells. (A) RT-qPCR for immune gene signature performed on cells after 
treatment with indicated LSD1 inhibitors for 24h. Catalytic inhibitors (TCP, GSK LSD1, 
and RN-1) and scaffolding inhibitors (SP-2509/2577) are compared to matched NHA 
controls using one-way ANOVA with FDR correction. (B) RT-qPCR data re-plotted with 
individual genes and including siRNA treatment for 48h. Fold change compared to 
DMSO control analyzed via one-way ANOVA with FDR correction. (C) Median 
fluorescent intensity of indicated receptors after 48h of LSD1 inhibitor treatment. 
Matched species and fluorophore isotype controls used to measure background 
fluorescence. Fold change compared to DMSO control analyzed via one-way ANOVA 
with FDR correction.* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001, ns = 
not significant. At least 3 biological replicates were used for all experiments. Error bars 








Fig 8. Expression of LSD1 after siRNA transfection of NHA and DIPG IV. Quantification 
of 3 biological replicates plotted at left as measured using ImageJ. Representative blot 
presented on the right.  
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The above receptors function either as NKG2D ligands or self-ligating receptors, and 
stimulation through these receptors increases NK cell activity and lysis of target cells. 
Given our observed upregulation of these receptors under LSD1 inhibition, we 
hypothesized that NK cells would lyse target DIPG cells more readily upon LSD1 
inhibition. Fluorescently labeled DIPG IV and VI cells were incubated with effector 
human NK cells at various effector to target (E:T) ratios. Across 3 unique healthy blood 
donors from which we expanded NK cells, we could observe increases in lysis in 2 
DIPG lines when treated with catalytic LSD1 inhibitors TCP and GSK LSD1, but 
inconsistently under scaffolding LSD1 inhibition by SP-2509 (Fig 9A). We hypothesize 
discrepancies between DIPG IV and VI to be due to higher basal levels of ULBP-4 in 
DIPG VI and greater upregulation of ULBP-4 in DIPG VI after pre-treatment with SP-
2509 (Fig 7C). Notably, the lysis efficacy of expanded healthy human donor T-cells was 
much lower than NK cells, and could not be augmented by LSD1 inhibitor pre-treatment 
(Fig 9B). We aimed to correlate genetic biomarkers of NK lysis by probing our gene 
signature from matched co-culture samples, and observed strong positive trends for 4 
genes in DIPG IV (Fig 9C) and 2 genes in DIPG VI (Fig 9D). Unexpectedly, a negative 
correlation could be found for 4-1BB (Fig 9E), traditionally a T-cell stimulatory factor, 
which could indicate alternative function during NK cell engagement.  Mice implanted 
with PKC-HA cells in the brainstem of syngeneic C57BL/6 mice and treated with 
catalytic LSD1 inhibitors (Fig 9F) showed increased expression of the gene signature in 
neural tissue harvested when mice were moribund (Fig 9G). Given that adaptive 
resistance to GSK LSD1 was seen in our mouse model (Fig 5G), we combined GSK 
LSD1 with NK cell infusion to model enhancement of innate immunity after LSD1 
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inhibition in vivo. Mice treated with intraperitoneal GSK LSD1 and intracranial human ex 
vivo expanded NK cells had the greatest reduction (43%) in tumor burden from baseline 
compared to vehicle control, GSK LSD1 alone, or NK cells alone (Figs 9H+I).  GSK 
LSD1 alone did not exert single agent anti-tumor efficacy in this human xenograft 
model, which contrasts with our results in mouse orthotopic models, likely due to 
species mismatch.  However, this highlights the anti-tumor effect of the combination of 








Fig 9. LSD1 inhibition upregulates innate immune receptors and sensitizes DIPG cells 
to NK cell lysis which correlates with unique genetic identifiers of response. (A) Lysis of 
target DIPG cells co-cultured with NK cells after 48h pre-treatment of target cells with 
LSD1 inhibitors (TCP 0.5mM, GSK LSD1 300μM, SP-2509 5μM). Treatments analyzed 
versus DMSO control using T-test with FDR correction. (B) Lysis of target DIPG cells 
co-cultured with T-cells after 48h LSD1 inhibitor pre-treatment. (C) DIPG IV RT-qPCR 
from matched co-culture experiments, genes with positive Pearson’s correlation R2 > 
0.80 are shown with 95% confidence intervals. (D) DIPG VI RT-qPCR from matched co-
culture experiments. (E) RT-qPCR from matched co-culture experiments, negative 
correlation with R2 > 0.80 shown with 95% confidence intervals. (F) Schematic of 
immunocompetent C57BL/6 PKC-HA brainstem mouse model. (G) RT-qPCR was 
performed on RNA extracted from PKC-HA mouse brains. Fold change is plotted versus 
PBS control. TCP and GSK LSD1 were compared to PBS via one-way ANOVA with 
FDR correction. (H) Images of orthotopic tumor luminescence in NSG DIPGIV-luc mice 
starting from day 0 prior to start of treatment. (I) Tumor burden of NSG DIPGIV-luc mice 
quantified (photons/sec/cm2) and analyzed for % change (delta) and linear regression 
(slope) between day 0 and day 21. * = p < 0.05 and ns = not significant. At least 3 




  To further validate our finding that catalytic LSD1 inhibition can enhance NK cell 
lysis of DIPG in vitro and in vivo, we re-visited our patient data for analysis using 
CIBERSORT. We found that significant NK cell infiltration predicts increased survival for 
H3-WT hemispheric tumors, but significant CD8 T-cell infiltrate predicts slightly worse 
survival. Brainstem tumors benefited less from NK infiltrate, but significant NK presence 
still shows superior patient survival versus significant CD8 T-cells in the brainstem (Fig 
10A). We next investigated how already-present or ex vivo infused immune cells would 
respond to LSD1 inhibition and treated expanded NK and T-cells with a panel of 
chromatin-modifier inhibitors, including our LSD1 suite. As has been known (102), T-
cells are sensitive to HDAC inhibition, but are fairly resistant to LSD1 inhibition except at 
higher doses of the scaffolding inhibitors. Conversely, NK cells are resistant to HDAC 
inhibition but highly sensitive to scaffolding LSD1 inhibitors, with no live cells detected 
even at 500 nM doses of SP-2509/2577 (Fig 10B). Catalytic LSD1 inhibitors are 
comparatively non-perturbing, with the IC50s against NK cells being 2-10X higher than 
doses needed to induce our gene signature. Given our data showing the scaffolding 
LSD1 inhibitors are cytostatic but not cytotoxic to NHA cells, we profiled the metabolism 
of both NK and T-cells after LSD1 inhibitor treatment, as active metabolism of nutrients 
has been shown to be crucial to anti-tumor effects of both cell types. Strikingly, the 
scaffolding LSD1 inhibitors completely suppress the metabolism of NK cells, rendering 
them metabolically quiescent but still alive at 48h post-treatment (Fig 10C). Collectively, 
this data suggests that catalytic LSD1 inhibitors may be used at therapeutic doses to 








Fig 10. NK cell tumor infiltration is predictive of survival benefit in pediatric high-grade 
glioma patients and catalytic LSD1 inhibitors are non-perturbing to mature NK and T-
cells. (A) CIBERSORT analysis of pHGG patient data sub-analyzed by tumor location 
and immune cell type. Survival curves show significant vs. non-significant presence of 
indicated immune cell in patient tissue. (B) Purified expanding T-and NK cells treated 
with indicated chromatin-modifier inhibitors for 120h and measured using AlamarBlue. 
(C) XF Mito Stress Test performed on NK and T-cells after 48h of LSD1 inhibitor 
treatment (TCP 0.5mM, GSK LSD1 300μM, RN-1 25μM, SP-2509/2577 5μM) and 
treatments compared to DMSO control analyzed by T-test with FDR correction. * = p < 
0.05. At least 3 biological replicates or unique donors were used for all experiments. 




Chapter 2: Effects of LSD1 inhibition on cytotoxic immune cells 
Background 
Cellular therapies are rapidly being investigated for applications in infectious 
disease, autoimmunity, and oncology. Numerous clinical trials are testing the 
combination of infused cell therapies with targeted therapies, including small molecules 
and antibodies, with the aim of increasing efficacy of the cell product at the disease site. 
Epigenetic drugs targeting chromatin modifiers are among these potential combinations, 
with available agents for a range of targets including acetylated histone readers (BETs), 
histone deacetylases, methyltransferases, and demethylases (103). The histone H3K4 
demethylase LSD1 has been investigated as a target in Ewing sarcoma and AML, 
where LSD1 inhibition induces differentiation of AML cells (104) and blocks fusion 
protein transcriptional targets in sarcoma (60). Among tumors with low mutational 
burdens, it has been proposed that epigenetic inhibitors can make these cancers more 
visible to the immune system by activating gene expression programs (105). Recently, it 
has been demonstrated that LSD1 inhibition can accomplish this by stimulating T-cell 
immunity in epithelial cancers (88, 89) and innate immunity in pediatric brain tumors 
(106).  
Available LSD1 inhibitors operate through two distinct binding mechanisms: 
irreversible catalytic site inhibitors and reversible scaffolding inhibitors. Both types of 
inhibitors can block the demethylase function, but scaffolding inhibitors also interfere 
with LSD1 in complex with other epigenetic regulators (39). LSD1 presence is critical for 
normal hematopoietic development in the terminal erythroid and megakaryocytic 
compartments (27, 28), but there remains little information on the effects of LSD1 
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inhibitors directly on mature cytotoxic T- and NK cells. In a combination treatment 
scheme, small molecule LSD1 inhibitors will also encounter infused immune cells in 
peripheral blood and the local tumor microenvironment. Ergo, it is crucial to understand 
how LSD1 inhibitors of differing potencies and binding mechanisms may affect T- and 
NK cells. Epigenetic regulation of NK cells by chromatin modifiers has previously been 
linked to methyltransferase EZH2 (107, 108), demethylases KDM5A (109) and JMJD3 
(110), and the deubiquitinase MYSM1 (111). Notably, Cribbs et al included a small 
molecule epigenetic compound screen for IFN-gamma secretion from NK cells, but only 
catalytic LSD1 inhibitors (TCP and GSK LSD1) were included at low doses (20µM and 
0.5µM, respectively). 
I have previously published that the scaffolding LSD1 inhibitor SP-2509 and its 
clinical successor SP-2577 potently suppress the viability and metabolism of NK cells 
(106). LSD1 has previously been implicated in metabolic regulation in adipose tissue 
(112) and red blood cells (113), but I was the first to show this effect in NK cells. In this 
chapter with NK cells kindly provided by Dr. Dean A. Lee, M.D., Ph.D., I further expand 
upon my previous findings to uncover an induced oxidative stress response that is 
unique to NK cells, compared to T-cells, and unique to scaffolding LSD1 inhibitors 
compared to catalytic inhibitors. I am the first to link LSD1 to redox response in NK 
cells, and I further delineate the critical role of glutathione (GSH) in NK cell cytotoxic 
response, monitoring of which is critical for use of NK cells as a treatment in infectious 




LSD1 inhibitors can bind to different sites of the LSD1 structure and elicit unique 
phenotypes in cells. Irreversible catalytic inhibitors TCP, GSK LSD1, and RN-1 form 
covalent adducts in the demethylation site of LSD1 and block LSD1 activity on histones 
and other target proteins (Fig 11A). Scaffolding inhibitor SP-2509 acts through a 
potential allosteric mechanism (79) and can disrupt LSD1 in complex with CoREST (39) 
in addition to the demethylation function (Fig 11A). I previously observed that 
scaffolding LSD1 inhibitors were more potent against NK cells compared to T-cells, into 
the nanomolar range for NK cells, using the AlamarBlue assay (106). Here I replicated 
doses used to induce NK reactivity in pediatric brain tumors, against NK cells to 
simulate co-administration and measured viability using amine-reactive dyes and flow 
cytometry. Catalytic inhibitors did not reduce viability of NK cells (q = n.s.), but 
scaffolding inhibitors were notably potent at doses 5-200X lower than catalytic inhibitors 
(Fig 11B, q < 0.001). T-cell viability also was reduced by scaffolding LSD1 inhibitors, but 
they displayed much greater resistance (Fig 11C, q = 0.004; Fig 11D, q < 0.01). I next 
examined if NK cell sensitivity to scaffolding LSD1 inhibitors was dose and time 
dependent and found that higher doses and longer incubation times amplified the 
cytotoxic effect (Fig 11E, q < 0.001). My previous publication also found metabolic 
suppression unique to scaffolding LSD1 inhibitors in NK cells (106). I was able to 
replicate these findings, observing that scaffolding LSD1 inhibitors abolish all oxidative 
phosphorylation in NK cells (Fig 11F, * = q < 0.01) and reduce OXPHOS to a much 








Figure 11. Scaffolding LSD1 inhibitors reduce viability and suppress metabolism in NK 
cells. (A) LSD1 inhibitors used and their respective properties. (B) Viability of NK cells 
after 48h treatment of LSD1 inhibitors (TCP: 1mM, GSK LSD1: 100µM, RN-1: 25µM, 
SP-2509: 5µM, SP-2577: 5µM) using amine-reactive viability dye analyzed via flow 
cytometry. (C) Viability of T-cells using the same method. (D) Viability of NK and T-cells 
under SP-2509 or SP-2577 treatment compared using unpaired t-test. (E) Dose 
response of SP-2509 and SP-2577 in NK cells at indicated time points using amine-
reactive viability dye. (F) Basal and maximal OXPHOS of NK cells after 48h treatment 
with indicated LSD1 inhibitors measured using XF Mito Stress Test on a Seahorse 
XFe96 analyzer. (G) Basal and maximal OXPHOS of T-cells using the same method. * 
= q < 0.01. All conditions are compared to DMSO control via t-test with FDR correction. 
At least 3 independent experiments are displayed (+/- SEM), sourced from 2 unique NK 




Given the extreme mitochondrial dysfunction induced by scaffolding LSD1 
inhibitors, I used other molecular probes to examine mitochondrial health in NK cells. 
Under scaffolding but not catalytic LSD1 inhibitor treatment, I observed a potent drop in 
healthy mitochondria (MitoTracker) and rise in mitochondrial superoxide production 
(MitoSOX) in NK cells (Fig 12A, * = q < 0.01). Notably, this effect could not be replicated 
in T-cells (Fig 12B, q = n.s.). When normalized to number of healthy mitochondrial, 
superoxide production was over 30X higher in NK cells compared to T-cells under 
scaffolding LSD1 inhibitor treatment (Fig 12C, * = q < 0.01). Interestingly, glycolysis was 
also reduced only in NK cells under scaffolding LSD1 inhibitor treatment, therefore 
metabolic effects of this compound class are not limited to mitochondria (Fig 12D, * = q 
< 0.01). We next investigated if drops in oxidative phosphorylation were dose 
dependent with SP-2509 and SP-2577 and found that even low doses (~315nM for 48h) 
could significantly reduce basal and maximal respiration in NK cells (Fig 12E, q < 
0.001). However, glycolysis reduction was dose dependent under SP-2509 and SP-








Figure 12. NK cells produce uncontrolled mitochondrial superoxide when treated with 
scaffolding LSD1 inhibitors. (A) NK cells treated for 48h with indicated LSD1 inhibitors 
were stained with MitoTracker Deep Red and MitoSOX Red combined with viability dye. 
Median fluorescent intensity (MFI) of APC channel (MitoTracker) and PE channel 
(MitoSOX) are plotted from live cells only. (B) T-cell MitoTracker and MitoSOX data 
using the same method. (C) NK and T-cell MitoSOX MFI divided by MitoTracker MFI 
indicates mitochondrial superoxide relative to healthy mitochondria number. (D) Basal 
glycolysis of NK and T-cells treated for 48h with LSD1 inhibitors measured using XF 
Mito Stress Test. (E) OCR dose response of SP-2509 and SP-2577 in NK cells treated 
for 48h and measured using XF Mito Stress Test. (F) Basal glycolysis dose response of 
SP-2509 and SP-2577 in NK cells treated for 48h and measured using XF Mito Stress 
Test. * = q < 0.01. All conditions are compared to DMSO control via t-test with FDR 
correction. Marked Seahorse data points indicate all treatment conditions are significant 
versus DMSO control. At least 3 independent experiments are displayed (+/- SEM), 




While mitochondrial function was not dose dependent in NK cells, but viability 
was, I performed dose responses examining mitochondrial number, superoxide 
production, and glutathione levels in NK cells treated with SP-2509 and SP-2577. I 
found superoxide production was time and dose dependent, but this could be blocked 
by co-supplementation with exogenous glutathione (Fig 13A, * = q < 0.05). Treatment 
with scaffolding LSD1 inhibitors reduced glutathione in a dose dependent manner, 
potentially explaining the uncontrolled mitochondrial superoxide levels. Here I also 
showed that glutathione co-supplementation blocks this reduction with SP-2509 and 
SP-2577 treatment (Fig 13B, * = q < 0.05). Mitochondrial number was also dose 
dependent, but interestingly not variable by time or glutathione supplementation, 
suggesting a rapid and oxidative stress-independent mechanism of mitochondrial 
damage by SP-2509 and SP-2577 (Fig 13C, q = n.s.). I next attempted to rescue 
mitochondrial oxidative phosphorylation and glycolysis by co-supplementation with 
antioxidants, both cell-wide (2.5mM GSH and 25µM Trolox) and mitochondrial-targeted 
(10nM mitoquinol (MQ) and 1nM SKQ1) (114, 115). I found that none of the antioxidants 
could restore mitochondria function (Fig 13D, q < 0.001) or glycolysis (Fig 13E, * = q < 
0.05), further suggesting metabolic defects caused by SP-2509 and SP-2577 are not 








Figure 13. Scaffolding LSD1 inhibitor-induced oxidative stress in NK cells is dose 
dependent and can be rescued with glutathione supplementation, but metabolism 
defects cannot. (A) MitoSOX dose response of SP-2509 and SP-2577 in live NK cells at 
indicated time points and rescued using 2.5mM glutathione ethyl ester (GSHee). (B) 
Glutathione dose response of SP-2509 and SP-2577 in live NK cells measured using 
mBCL and rescued using 2.5mM GSHee. (C) MitoTracker dose response of SP-2509 
and SP-2577 in live NK cells and attempted rescued using 2.5mM GSHee. (D) 
OXPHOS of NK cells treated with scaffolding LSD1 inhibitors for 48h and attempted 
rescue with cell-wide antioxidants (GSHee and Trolox) and mitochondrial-targeted 
antioxidants (mitoquinol (MQ) and SKQ1) measured using XF Mito Stress Test. (E) 
Basal glycolysis of NK cells treated with scaffolding LSD1 inhibitors for 48h using the 
same method and measured using XF Mito Stress test. * = q < 0.01. All conditions are 
compared to DMSO control via t-test with FDR correction. Marked Seahorse data points 
indicate all treatment conditions are significant versus DMSO control. At least 3 





I concluded by exploring functional determinants of NK cell biology, primarily their 
receptor phenotype and ability to lyse target cells. Multicolor flow cytometry revealed 
that only scaffolding LSD1 inhibitors reduce activating receptors on NK cells (Fig 14A, * 
= q < 0.05). Next, I co-incubated LSD1 inhibitor pre-treated NK cells with labeled K562 
target cells to assess their cytotoxic function. Here I observed that all LSD1 inhibitors 
reduced NK lysis ability, with SP-2509 and SP-2577 being by far the most potent (Fig 
14B, * = q < 0.05). I hypothesized that glutathione co-supplementation could restore NK 
function, and indeed I found that viability was rescued by GSH (Fig 14C, * = q < 0.05). 
Furthermore, low doses of SP-2509 did not compromise lytic function, suggesting the 
observed metabolic suppression did not hinder NK cytotoxicity (Fig 14D, * = q < 0.05). 
Concurrent 2.5mM GSH supplementation could rescue cytotoxic functions from near 
zero at high doses of SP-2509 after 48h, indicating that target cell killing by NK cells is 
strongly regulated by redox balance under scaffolding LSD1 inhibitor treatment (Fig 
14D, * = q < 0.05). My proposed model of scaffolding LSD1 inhibitors in NK cells is 
metabolic suppression at low doses and an independent pro-oxidative induction at high 








Figure 14. NK cell ligand expression and cytotoxicity are impaired by scaffolding LSD1 
inhibitors, but viability and cytotoxicity can be rescued with glutathione supplementation. 
(A) NK cells treated for 48h with indicated LSD1 inhibitors display reduced activating 
ligand expression. (B) NK cell cytotoxicity against K562 target cells is reduced by 48h 
pre-treatment with indicated LSD1 inhibitors. (C) Viability dose response of SP-2509 
and SP-2577 in NK cells treated with and without 2.5mM GSHee supplementation. (D) 
NK cell cytotoxicity against K562 target cells after 48h pre-treatment with SP-2509, with 
and without GSHee supplementation. (E) Working model of scaffolding LSD1 inhibitor 
effects on NK cell metabolism, redox state, and function. * = q < 0.01. All conditions are 
compared to DMSO control via t-test with FDR correction. At least 3 independent 




As a potential mediator of metabolic and redox mechanism in NK cells, 
preliminary data was obtained regarding the expression of the LSD1/CoREST/GFI1 
complex and histone methylation status in NK and T-cells during LSD1 inhibitor 
treatment. After 48h of treatment, NK cells lost expression of LSD1 (Fig 15A), CoREST 
(Fig 15B), and GFI1 (Fig 15C) under treatment with scaffolding LSD1 inhibitors, but not 
catalytic inhibitors. Preliminary data indicates this effect is not recapitulated in T-cells, 
but more replicates are required to confirm this. Interestingly, NK cells exhibited stable 
H3K4me2 under catalytic inhibitor treatment, but not scaffolding inhibitors. Meanwhile, 
T-cells have much lower basal H3K4me2 compared to NK cells, and this mark 








Figure 15. LSD1 complex expression is dysregulated in NK cells under scaffolding 
LSD1 inhibitor treatment. (A) Western blot of LSD1 in NK (n = 3) and T-cells (n = 1) 
after 48h incubations of LSD1 inhibitors (TCP: 1mM, GSK LSD1: 100µM, RN-1: 25µM, 
SP-2509: 5µM, SP-2577: 5µM). (B) Western blot of GFI1 in NK cells (n = 3) after 48h 
incubations of LSD1 inhibitors. (C) Western blot of CoREST in NK (n = 3) and T-cells (n 
= 1) after 48h incubations of LSD1 inhibitors. (D) Western blot of H3K4me2 in NK (n = 
1) and T-cells (n = 1) after 48h incubations of LSD1 inhibitors. Quantifications are 




Chapter 3: Immune microenvironment of pediatric high-grade gliomas (pHGGs) 
Background 
Pediatric high-grade gliomas (pHGGs) are aggressive brain tumors in children 
with poor prognoses and limited therapeutic options. A frequent mutation in pHGG 
subtypes are amino acid substitutions in histone tails, specifically histone H3.1 and 
H3.3. Lysine-to-methionine (H3.1/3.3-K27M) mutations occur in brainstem and midline 
tumors almost exclusively, and indicate the worst prognosis among pHGGs. 
Hemispheric tumors arise in the cerebral cortex and are often H3-WT but sometimes 
feature H3.3-G34R/V mutations, which have worse prognosis than H3-WT but 
significantly better than H3.1/3.3-K27M (101). Radiotherapy is the standard of care for 
brainstem tumors, while hemispheric tumors may add chemotherapy or targeted 
therapy in combination with radiotherapy depending on detected mutations (116). There 
have been no significant advances in pHGG therapy and these cancers are in 
desperate need of inventive and efficacious modalities. 
Clinical trials have recently began investigating immuno-modulating therapies for 
pHGG, including vaccines (NCT01130077, NCT03334305, NCT03615404), immune 
checkpoint blockade (NCT03690869), and cytokine therapy (NCT03330197). For these 
interventions to work properly, there must be cytotoxic immune cells present either in 
the tumor, or in the peripheral blood that can traffic to the tumor site, to be stimulated 
and become more active. These trials are not designed to account for mutational and 
anatomical differences among pHGG patients, which may play a role in efficacy of 
immunotherapies if immune infiltration differs by these factors. At present, there have 
been limited investigations on the immune status of pHGGs that include hemispheric 
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and brainstem tumors, and how different immune cell subtypes may contribute to 
patient prognosis.  
Within this chapter, with assistance from Dr. Linghua Wang in the Genomic 
Medicine department of MD Anderson, I use the computational method CIBERSORT to 
investigate a patient dataset of 247 pHGGs, which includes both H3-WT hemispheric 
and H3-K27M brainstem gliomas. I find that distributions of immune cells differ between 
these tumor locations and that improved patient survival can be predicted by immune 
cell types. Significant presence of regulatory T-cells, memory B-cells, eosinophils, and 
dendritic cells indicate better patient prognosis for hemispheric tumors, but not 
brainstem tumors. I further find that brainstem tumors, compared to hemispheric tumors, 
have greater levels of detectable cytokines and growth factors known to suppress 
immunity, including IL-6, IL-10, and VEGF. I correlate patient survival with 
immunosuppressive genes IL10 and VEGF, implicating secreted factors as important 
across all pHGGs and potentially identifying a new therapeutic target network. 
Data 
I first compared distributions of immune cells that could be detected by the 
CIBERSORT platform and their differences between hemispheric and brainstem 
tumors. I found more detectable amounts of CD8 T-cells, NK cells, CD4 T-regs, M1 
macrophages, eosinophils, and activated mast cells in hemispheric tumors, but more 
detectable amounts of activated dendritic cells (DCs) and neutrophils in brainstem 
tumors (Fig 16A). I next examined if significant immune infiltrate of each cell type held 
prognostic value for patient survival outcomes. In the lymphoid compartment, I found 
that memory B-cells (Fig 16B), CD4+ regulatory T-cells (Fig 16C, p = 0.01), and 
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activated DCs (Fig 16D) suggest improved patient survival in hemispheric pHGGs when 
patients had significant presence of each cell type. Notably, this did not hold true for 








Figure 16. Immune cell infiltrates differ by tumor location and can predict survival benefit 
in hemispheric pHGG. (A) Distribution of CIBERSORT output for immune cell types and 
segmented by tumor location. (B) Survival curves of hemispheric and brainstem pHGG 
patients with detectable amounts of memory B-cells. (C) Survival curves of hemispheric 
and brainstem pHGG patients with detectable amounts of regulatory T-cells. (D) 
Survival curves of hemispheric and brainstem pHGG patients with detectable amounts 




I next examined if cell types in the myeloid compartment were prognostic and 
varied by pHGG tumor location. I again found that brainstem tumors never benefit from 
immune infiltrate, but positive associations were found in hemispheric tumors for 
eosinophils (Fig 17A, p = 0.05), M1 macrophages (Fig 17B), and activated mast cells 
(Fig 17C). Interestingly, neutrophils were negatively prognostic for both hemispheric 
(Fig 17D, p = 0.03) and brainstem (Fig 17D, p = 0.01) locations. I compared 
hemispheric to brainstem tumors using the average patient survival for each type, 
aiming to profile which immune cells types could predict long-term survivors, or the 
“long-tail” seen in immunotherapy regimens (117). Here I found significant differences 
by tumor location (* = p < 0.05) for NK cells, regulatory T-cells, dendritic cells, memory 
B-cells (Fig 18A), and eosinophils, monocytes, and M1 macrophages (Fig 18B). 
Cytotoxic CD8 T-cells and M2 macrophages could predict small numbers of long-term 
survivors, but the differences were non-significant, and detectable presence of these 








Figure 17. Myeloid immune infiltrates indicate improved survival for hemispheric pHGG 
except for neutrophils. (A) Survival curves of hemispheric and brainstem pHGG patients 
with detectable amounts of eosinophils. (B) Survival curves of hemispheric and 
brainstem pHGG patients with detectable amounts of M1 macrophages. (C) Survival 
curves of hemispheric and brainstem pHGG patients with detectable amounts of 
activated mast cells. (D) Survival curves of hemispheric and brainstem pHGG patients 








Figure 18. Immune infiltration only correlates with long-term survivors in hemispheric 
pHGG. (A) All detectable lymphoid cell types plotted as hemispheric v. brainstem by 
patient survival. (B) All detectable myeloid cell types plotted as hemispheric v. 
brainstem by patient survival. Average survival calculated using all patients regardless 
of detectable CIBERSORT output. * = p < 0.05 by unpaired t-test, no multiple 




Given the complete lack of survival benefit in brainstem tumors across several 
immune cell types, I hypothesized the local tumor microenvironment may be 
immunosuppressive and lacking in inflammatory signals. I investigated the RNA-Seq 
data used for CIBERSORT and plotted immunosuppressive genes segregated by tumor 
location. Brainstem tumors uniformly expressed more immunosuppressive genes, with 
significant differences (Fig 19A, * = p < 0.05) found for IDO2, IL10, FASLG, IL6, 
VEGFA, and VEGFC. I next sought to examine if I could detect secretory cytokines from 
immune cells within the bulk RNA-Seq data and if they differed by tumor location. Using 
patients with significant NK cell infiltrate as a model, I found hemispheric tumors 
expressed significantly more TGFβ1, but less IFNG and GZMB, than brainstem tumors 
(Fig 19B, * = p < 0.05). TGFβ family members are well known to suppress NK function 
(118), but NK cells are able to confer survival benefit in hemispheric tumors (106), 
suggesting NK activating signals are expressed highly enough in hemispheric pHGG to 
compensate. For tumors with significant NK infiltrate, the immunosuppressive genes 
GZMB and SLAMF6 correlate significantly with survival in hemispheric tumors (Fig 19C, 
p < 0.05), and no immunosuppressive genes correlated in brainstem tumors. When 
examining all patients together, I found that IL10, FGL2, VEGFB, and VEGFC were 
significantly correlated with hemispheric pHGG survival (Fig 19D, p < 0.05). In 
brainstem tumors, IL10 and IDO2 were significantly correlated (Fig 19E, p < 0.05), 








Figure 19. Brainstem pHGG exhibit greater immunosuppression which can be 
correlated with survival. (A) Gene expression of immunosuppressive factors from all 
patients regardless of detectable CIBERSORT output. (B) Gene expression of secreted 
cytokines from patients with significant NK infiltration by CIBERSORT. (C) Expression v. 
survival plot of immunosuppression genes with significant Spearman correlations (p < 
0.05) in hemispheric pHGG patients with significant NK infiltration by CIBERSORT. (D) 
Expression v. survival plot of immunosuppression genes with significant Spearman 
correlations (p < 0.05) in all hemispheric pHGG patients. (E) Expression v. survival plot 
of immunosuppression genes with significant Spearman correlations (p < 0.05) in all 







 This chapter identifies LSD1 as a novel cytotoxic target and epigenetic immune-
suppressor in pHGG. There have been several published epigenetic therapeutic targets 
in DIPG as mentioned in the introduction, but I am the first to explore combination 
immunotherapy with epigenetic therapy. NK cell infusion has been previously shown to 
be effective against human and mouse adult glioblastoma in pre-clinical models (119). 
The NK expansion method used in this chapter can be monitored in vivo via imaging 
(120), and furthermore has been shown to be efficacious and trackable in 
medulloblastoma mouse models (121). NK cell therapy using expanded cells 
independent of donor is a true “off-the-shelf” immunotherapy product (122), and has 
been shown to be safe in phase 1 clinical trials (123), including pediatric brain tumor 
patients (124). The knowledge base is in place for a translatable clinical trial of catalytic 
LSD1 inhibitors combined with expanded NK cells, but challenges remain to address 
the PK/PD of available LSD1 inhibitors for neuro-oncology applications, as well as 
effective delivery methods of NK cells to the tumor site. 
 While I am not the first to explore boosting anti-tumor immunity through LSD1 
modulation (88, 89), I am the first to compare catalytic inhibitors versus scaffolding 
inhibitors, as well as the use of LSD1 inhibition in a non-epithelial-derived cancer. An 
intriguing result is the efficacy of a potent catalytic LSD1 inhibitor, GSK LSD1, 
compared to a non-selective catalytic inhibitor (TCP) and a potent scaffolding inhibitor 
(SP-2577). GSK LSD1 shows potential as a monotherapy in vivo, however I observed 
acquired resistance, which is not unexpected with targeted therapy in gliomas (125). 
94 
 
This result shows that GSK LSD1 may have favorable PK properties to the brain, 
though another study saw otherwise (61), but since they used a medulloblastoma model 
it is possible GSK LSD1 can reach hemispheric but nor cerebellar tumors. Interestingly 
both TCP and SP-2577 were worse than my control arm, suggesting potential toxicity at 
our doses, though this should be confirmed with more mice per group and a separate 
mouse model. We also used an older formulation of SP-2577, so a newer version may 
prove more efficacious (source: meeting with Salarius Pharmaceuticals).  
Other noteworthy LSD1 inhibitors have emerged since I began this study, and 
they warrant testing in pHGG models (Table 2). Others have observed that catalytic and 
scaffolding LSD1 inhibitors differ in their anti-cancer efficacy (126), therefore 
mechanism of action must be kept in mind for future studies in pHGG. Two catalytic 
inhibitors independently developed by Takeda and RIKEN show potential as neuro-
oncology therapeutics by their ability to treat brain-resident T-ALL (127) and alter mouse 
neurological function (128). The potent catalytic inhibitor ORY-1001 shows excellent 
activity in AML (83) and some solid tumors (62, 129-131), and Oryzon is developing 
LSD1 inhibitors for neuropsychiatric applications and therefore may be open to funding 
a brain tumor pre-clinical study. For direct cytotoxicity of pHGG via scaffolding inhibitors, 
a company in Sweden is developing brain-penetrant inhibitors with a similar allosteric 
mechanism to SP-2509 and SP-2577. Beactica AB showcased their BEA-17 compound 
at AACR 2019 (abstract #3843), reporting µM accumulation in the brain, efficacy in PDX 
glioblastoma mouse models, and in vitro synergy with HDAC inhibitors. The DRD2-
antagonist ONC201 may present a logical combination therapy with NK cells for pHGG, 
as it was shown pre-clinically to enhance NK infiltration of tumors (132) and modulate  
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Table 2. Next-generation LSD1 inhibitors for pHGG therapy 






































































metabolism of gliomas (137). Furthermore, ONC201 may present durable single-
agent activity against glioblastomas and H3-K27M pediatric gliomas after conclusion of 
its clinical trials (138-141). I also suggest that future studies of NK cells in pHGG models 
utilize standard-of-care chemotherapy and radiation, which have been shown pre-
clinically to synergize with NKG2D signaling (142) and enhance CAR-T infiltration via 
lymphodepletion (143), and clinically to correlate with survival benefit and NK infiltration 
after dendritic cell vaccination (144). 
Chapter 2 
My work is the first to show therapeutic inhibition of LSD1 via scaffolding 
inhibitors initiates functionally relevant pro-oxidative effects in NK cells. While the direct 
mechanism of LSD1 redox regulation in NK cells remains to be discovered, LSD1 has 
been linked to oxidative stress in two previous reports. In studies of macrophage 
resistance to hydrogen peroxide, Tokarz et al found that inhibiting LSD1 with SP-2509 
increases cell viability and reduces superoxide, the opposite of my observations (145). 
The mechanism in macrophages was driven by short lived (<9hrs) enhancement of 
SOD2 transcription by reversal of demethylation of H3K4me2 induced by LPS 
stimulation. They did not compare SP-2509 to other LSD1 inhibitors with catalytic 
binding nor did they examine glutathione levels. Their findings demonstrate the lineage-
specific effects of scaffolding LSD1 inhibitors, as I observed between NK and T-cells. 
Mishra et al observed that silencing of LSD1 with siRNA in retinal endothelial cells 
increased H3K4me1/H3K4me2 at the promoter of GCLC, the key enzyme in GSH 
synthesis that binds glutamate to cysteine (146). They also saw increased binding of 
NRF2 at the GCLC promoter under LSD1 siRNA along with increased GCLC 
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expression. This is again opposed to my observation of LSD1 preserving glutathione 
levels, however no LSD1 inhibitors were used in their investigation so it cannot be said 
if binding sites on LSD1 play a role or if the differential response is due to tissue type. 
Another possible explanation for GSH loss under LSD1 inhibition is downregulation of 
glucose transporters, which has previously been observed with LSD1 knockdown (147). 
Reductions in glucose import would dampen the pentose-phosphate pathway, leading 
to reduced NADPH production and an inability to recharge GSH from its oxidized GSSG 
form. Potential NK cell dependence on cystine importer SLC7A11 expression would 
make them sensitive to glucose deprivation via disulfide accumulation, already a noted 
vulnerability in cancer cells (148, 149). The above findings may be potential 
mechanisms connecting LSD1 to glutathione in NK cells, but I am the first to observe 
key differences using a thorough suite of catalytic and scaffolding LSD1 inhibitors. 
GSH has been previously demonstrated to play an important role in immune cell 
function, including detailed mechanisms in T-cells and correlative nutritional studies in 
NK cells. Kurniawan et al recently reported an elegant mouse model of GSH-deficiency 
in regulatory T-cells, where GSH controls serine metabolism through ASCT1 expression 
and subsequently activates mTOR/SMAD3/FoxP3 signaling to endow Tregs with their 
suppressive capabilities (150). GSH was also shown to be critical for cytotoxic T-cell 
responses via a NFAT-dependent glycolysis mechanism (151), but this has been found 
to be dispensable in NK cells (152). Mitochondrial metabolism has also been suggested 
to be critical to NK function. Intratumoral hypoxia was shown to promote tumor escape 
from innate immunity potentially by suppression of NK OXPHOS (153), and fatty acid 
uptake by NK cells in obese patients reduced their OXPHOS and lytic function (154). 
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Herein I have shown NK cells maintain high cytotoxicity despite markedly suppressed 
mitochondrial OXPHOS, and that GSH can rescue cytotoxic function independently of 
oxygen consumption or lactic acid production. Notably, neither of these reports 
investigated glutathione or oxidative stress, but an earlier report found obese mice had 
defective leukocyte lysis and lowered GSH levels (155). This phenotype could be 
rescued by adding eicosapentaenoic and docosahexaenoic acids to the diet, suggesting 
dietary interventions can be used to combat immune cell oxidative stress. 
Given my findings that scaffolding LSD1 inhibition depletes GSH and blunts NK 
activity, it may be possible for oral supplementation of GSH or its precursors to be 
combined with LSD1 inhibitors in patients. A previous report showed cysteine and 
theanine supplementation can boost NK cytotoxicity in humans, but the authors did not 
measure glutathione levels despite cysteine being the rate-limiting amino acid in GSH 
synthesis (156). In other human trials, oral GSH supplements could boost cytotoxicity 
against K562 cells (157, 158), and low glutathione in blood tracked with low cytotoxicity 
in autistic patients (159), however these studies are flawed as whole PBMCs were used 
for the cytotoxicity assays instead of isolated NK cells. In vitro NK functions can also be 
augmented against infectious M. tuberculosis (160), and rescued after treatment by 
tri/dibutylin (161) or reactive nitrogen metabolites (162), by GSH supplementation. The 
natural compound adenanthin produces similar cytotoxicity defects and ROS 
accumulation in NK cells at similar concentrations to scaffolding LSD1 inhibitors (163). 
While adenanthin does not deplete glutathione nearly as potently as SP-2509/2577, NK 
cell cytotoxicity could be rescued with N-acetylcysteine which can replenish GSH levels. 
Adenanthin is a proposed peroxiredoxin 1 (PRDX1) inhibitor, which reduces hydrogen 
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peroxides and alkyl hydroperoxides, and may be a downstream mediator of the LSD1 
inhibitor effect on GSH loss and cytotoxicity suppression (164). 
Adding to the above previous knowledge, my data highlights the crucial role of 
GSH in innate immune responses and defines a new role for LSD1 and potential 
complex members in maintaining NK cell redox status. The tower domain of LSD1 and 
its interactions with CoREST may play a mechanistic role in this phenomenon, given 
that catalytic LSD1 inhibition does not phenocopy scaffolding LSD1 inhibition. RNA-Seq 
data shows that expanded NK cells maintain expression of LSD1, CoREST, HDAC1, 
HDAC2, and GFI1 compared to naïve NK cells from the same donor (manuscript in 
preparation by Dean A. Lee, M.D., Ph.D.), indicating the LSD1 complex may remain 
important for NK cell oxidative balance in patients treated with LSD1 inhibitors. By 
linking antioxidants to NK cell lytic ability independent of metabolism, I propose that 
future investigations of LSD1 inhibition and NK cell therapy efficacy incorporate 
oxidative stress as an investigative endpoint. 
Chapter 3 
I have uniquely identified hemispheric tumors as immune-modulated vs. 
brainstem tumors in collective pHGG patient data. I also implicate the tumor 
microenvironment and secreted cytokines as mediators of the lack of survival benefit 
from immune infiltrate in brainstem pHGG. Unanswered questions remain regarding 
roles of histone mutations vs. anatomical location in these disparate immune 
phenotypes. I lacked statistical power to compare H3-WT brainstem, H3-K27M midline, 
and H3-G34R/V hemispheric tumors to their larger cohort mates. These tumors exist, 
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but are rare, and therefore engineered mouse models may be able to examine 
differences in immune infiltrates in a controlled study. 
A handful of previous publications have investigated neuro-oncology immune 
infiltrates using a combination of computational and live tissue methods, as well as 
cohorts of adult glioblastoma, pediatric gliomas, or a mixture of the two. Tang et al 
recently published an immune risk score (IRS) based upon CIBERSORT data in cohorts 
of adult glioblastoma (165). In their analysis, they found low numbers of activated NK 
cells correlated with poor patient prognosis, matching our observations in hemispheric 
pHGG (106). However, they also found that significant infiltration of memory B-cells, 
activated dendritic cells, and M1 macrophages were negatively prognostic, the opposite 
of our observations. They also did not report on eosinophils, neutrophils, or regulatory 
T-cells, possibly because these datasets did not report significant infiltration of these 
cell types. For single gene correlations, they found IDO and GZMB to be negatively 
prognostic with regards to their IRS score. This was again opposite of my observations, 
however I correlated expression directly with patient survival, not risk score. Other 
reports have shown distinct phenotypes of immune cells present in adult gliomas 
compared to pediatric (166) which may explain these observational differences. 
Bockmayr et al developed their own immune signature algorithm to analyze a 
dataset of over 1,000 samples that included both adult glioma and pHGG (167). Their 
analysis found that H3-WT gliomas had a significant enrichment in endothelial gene 
signatures compared to H3-mutated pHGGs, suggesting increased vascularization of 
H3-WT tumors. This hypothesis is being investigated using mouse models of brainstem 
and hemispheric pHGG (168). They also found that tumors rich in antigen-presenting 
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cells (APCs), such as dendritic cells and helper T-cells, had a favorable prognosis if the 
tumor also contained cytolytic cells (CD8 T-cells and NK). H3-WT tumors in this cohort 
contain 6-7X more adult gliomas than pHGGs, and the authors did not separate these 
cases in their analyses. However, by examining H3-G34R/V pHGGs compared to H3-
K27M pHGGs, I can make partial conclusions based upon tumor location in pediatric 
patients from this data. H3-G34R/V tumors presented much higher proinflammatory 
signaling compared to H3-K27M, and tumors with a diffuse intrinsic pontine glioma 
(DIPG, aka brainstem pHGG) diagnosis followed the same trend when compared to 
anaplastic astrocytoma and glioblastoma from the hemispheres. However, I cannot rule 
out the contribution of the H3-G34R/V mutation in these observed phenotypes 
compared to H3-WT hemispheric pHGG. 
Lieberman et al used both gene expression as well as IHC and functional assays 
to assess immune infiltrate in pediatric tumors exclusively, allowing direct comparisons 
of DIPG and hemispheric pHGG (169). I confirmed their observations that DIPG 
express lower amounts of TBFβ1 but higher amounts of VEGFα compared to pHGG. 
Their overarching hypothesis was that lack of immunosurveillance in DIPG was 
responsible for the low number of immune infiltrates, particularly T-cells. However, I did 
not find that increased presence of dendritic cells correlated with improved survival in 
brainstem pHGG patients. Furthermore, it has been shown that DIPG patients produce 
tumor-specific T-cells for the K27M antigen (170), suggesting that tumor 
microenvironment and trafficking of cytotoxic leukocytes plays a larger role. Adaptive 
tumor immunity in pHGG may be a candidate for anti-CD40 therapy, given that my 
paradoxical finding of massive survival benefit from CD4 T-regs was previously 
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observed in checkpoint inhibitor-refractory triple-negative breast cancer (TNBC) mouse 
models and melanoma patients (171). 
Collectively, this data combined with my findings suggests brainstem pHGGs 
possess a harshly immunosuppressive microenvironment lacking in inflammatory 
signals (166, 167, 169), potentially explaining why immune infiltrate in these tumors is 
never positively prognostic compared to hemispheric pHGGs. It should be noted that 
local neuroinflammation caused by infused CAR-T therapy was shown to be fatal in 
mouse models (172), indicating that caution must be used when attempting to stimulate 
cytokines in brainstem pHGGs. Another cogent hypothesis is that vascular differences 
exist between these tumor locations (167, 168, 173), preventing the influx of immune 
cells to the tumor site. Going forward, immunotherapeutic modalities for pHGG will need 
to consider tumor location when designing new interventions. I suggest that hemispheric 
pHGGs may respond well to vaccines, checkpoint blockade, and macrophage depletion, 
while brainstem pHGG will likely benefit more from carefully titrated adoptive cell 
therapies, epigenetic modulation, and new surgical delivery techniques. 
Future directions 
Catalytic LSD1 inhibitors combined with NK cell infusion presents a promising 
new therapeutic modality for pHGG, but more pre-clinical exploration would be helpful 
before a clinical trial is initiated. Our mouse models of pHGG were incomplete in terms 
of exploring hemispheric versus brainstem tumor locations and can be improved. We 
did not observe good engraftment of PKC-HA cells in the brainstem (~50%), and PKC-
HA cells also did not recapitulate our gene signature in vitro (data not shown). As such, 
they may not be an appropriate model to study immune interactions in brainstem pHGG 
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after LSD1 inhibition. An immunocompetent H3-K27M brainstem pHGG model was 
recently developed by St Jude Children’s Hospital and may be both easier to work with 
and recapitulate human DIPG biology more accurately (174). Xenografting of human 
DIPG cells into NSG mouse brainstems should also be attempted, along with usage of 
convention-enhanced delivery to the pons (96, 175), as a comparison to systemic 
delivery of inhibitors and immune cells (172).  
The newly developed LSD1 inhibitors explored above can be tested for ability to 
activate the gene signature and cause selective cell death. Testing of the orally 
bioavailable version of GSK LSD1, GSK2879552, is also warranted. Further exploration 
of the mechanism of enhanced NK lysis of DIPG by LSD1 inhibition should examine the 
functions of SLAMF7, RAET1E, and MICB by blocking the cognate SLAMF7 and 
NKG2D receptors on NK cells in co-culture experiments. The negative correlation of 4-
1BB gene expression with NK lysis is intriguing and should be confirmed with improved 
antibodies to detect 4-1BB protein on DIPG cells after LSD1 inhibition. This finding also 
may indicate other members of the TNF family of receptors, including CD40, OX40, 
CD27, and GITR, have influence on NK lysis of DIPG. 
The artificial antigen-presenting cell (aAPC) expanded NK cells are easy to work 
with and safe, but do not incorporate cellular engineering that is being explored in CAR-
T research. Dr. Katayoun (Katy) Rezvani at MD Anderson has published exciting clinical 
trial results of CAR-NK cells modified to secrete interleukin-15 (176), which I have 
shown is a potent cytokine that stimulates and sustains NK and CD8+ T-cells in vivo 
(177). Her lab has also shown pre-clinical efficacy of engineered NK cells that lack 
suppressive receptors in glioblastoma models (source: internal MD Anderson seminar; 
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Shaim et al., BioRxiv pre-print), and a recent publication by another group supports 
another portion of their NK engineering methodology (178). It should be noted the 
Rezvani lab NK cells are expanded from cord blood CD34+ hematopoietic progenitor 
cells, rather than from mature NK cells from adult peripheral blood. It is unknown what 
the efficacy of these cord blood-derived NK cells are against DIPG, or how they may 
respond to LSD1 inhibitors. Their CAR-NK research is now being developed in 
collaboration with Takeda Pharmaceuticals, whom also developed brain-penetrant 
LSD1 inhibitors (T-448/TAK-418) and may be ideal partners for a pHGG LSD1+NK 
project. 
The function of LSD1 in NK cell metabolism and redox needs further exploration 
to fully define the mechanism. It is not known whether catalytic LSD1 inhibitors also 
reduce GSH in NK cells and if this is the cause of their cytotoxicity defect. Furthermore, 
to implicate GSH loss in viability/metabolism/cytotoxicity, NK cells can be expanded in 
cystine-free media or treated with BSO/cystine-degrading enzymes (explored in the 
addendum section) to block GSH synthesis. Another control would be to use 
CRISPR/Cas9 to mutate domain interfaces or remove LSD1 entirely from NK cells, and 
observe if the metabolic and lytic defects manifest. These experiments would aid in 
identifying any potential off-target effects of LSD1 inhibitors in NK cells. It has been 
shown that SP-2509 induces protein instability in LSD1 (79), but this was not explored 
for CoREST or GFI1 in their paper. Cycloheximide chase and proteasome inhibition 
experiments on the LSD1 complex in NK cells would determine if this effect is 
conserved, along with qPCR for the corresponding genes to explore transcriptional 
regulation. If the loss of detectable protein is due to proteasomal degradation, a dose 
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response would explore if loss of the LSD1 complex tracts with loss of cytotoxic 
function. Finally, chromatin-immunoprecipitation sequencing (ChIP-Seq) could be 
employed to identify what genes may lose LSD1 complex member binding in NK cells 
under LSD1 inhibition. 
CIBERSORT analysis uncovered new aspects of immune infiltrate in pHGG 
patient data, but it is only an inferential computational technique. Ideally, my findings 
would be followed up with a comprehensive study of pHGG tissue samples, with IHC 
and IF slide sections looking for these immune cell types. By scoring patient tissue it 
could be directly compared to the CIBERSORT estimates of prognostic benefit. 
However, this is challenging as the RNA-Seq data used is the largest comprehensive 
pHGG dataset that includes gene expression data. Other datasets only have genomic 
sequencing, copy number, or methylation information that cannot be used for 
CIBERSORT or similar techniques. There is also not a large collective tissue bank of 
pHGG owing to the rarity of these tumors and inconsistencies in tissue collection and 
processing among medical centers. Despite these limitations, a small, focused 











Proteasome inhibitors and cystine balance 
My rotation project in the Chandra lab in spring 2015 was a follow-up to the 
thesis work of a recent Ph.D. graduate at the time, Christa A. Manton. Aims of her 
project were to understand the mechanisms and efficacy of proteasome inhibitors in 
glioblastoma. One of the interesting observations of her work was that supplementation 
of cells with N-acetylcysteine (NAC) massively reduced cell death induction by 
proteasome inhibition (179). This was confirmed by a separate group using patient-
derived glioblastoma cells (180). Importantly, Dr. Manton showed that NAC 
supplementation raised glutathione (GSH) levels, but GSH supplementation could not 
recapitulate the cell death rescue phenotype as NAC could. This suggests that available 
cysteine plays roles outside of glutathione generation that can affect cell death signaling 
under proteasome inhibition.  
For my rotation project, we worked with Dr. George Georgiou at the University of 
Texas at Austin, who had recently developed a recombinant enzyme the degrades free 
cystine, dubbed cyst(e)inase. We hypothesized that depletion of cysteine may sensitize 
glioma cells to proteasome inhibitors, with the hope of using very low doses to achieve 
a synergistic effect. I began by profiling the sensitivity of adult glioma and pediatric 
DIPG cells to proteasome inhibitors after 48h drug treatment (Fig 21A). Bortezomib was 
the most potent with IC50s less than 10nM in LN18 and DIPG IV; interestingly DIPG VI 
and XIII were uniformly quite resistant to proteasome inhibition, with IC50s >100nM. I 
next tested cyst(e)inase as a single agent against DIPG cells, where I observed no 
viability reduction but a dose-dependent drop in growth for DIPG IV with an IC50 of 
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~300nM after 48h (Fig 21B). I next assessed the primary function of cyst(e)inase by 
measuring glutathione (GSH) levels, as cysteine is the rate-limiting step for GSH 
synthesis. Buthionine sulfoximine (BSO) was used a positive control as it inhibits the 
enzymatic linking of cysteine to glutamate in GSH synthesis. As a rescue control, I used 
GSH ethyl ester (GSHee), a cell permeable form of GSH. A dose-dependent reduction 
in GSH was seen after 48h, with 100nM cyst(e)inase being equivalent to 1mM BSO (Fig 
21C). Use of 2mM GSHee could rescue GSH levels back to baseline even with 100nM 
cyst(e)inase, demonstrating specificity of the enzyme for cysteine in cells. Combination 
of proteasome inhibitors and cyst(e)inase in LN18 cells did not show enhancement of 
cell death after 48h treatment (Fig 21D). However, DIPG IV showed cell death 
enhancement at 10nM doses of carfilzomib after 48h treatment (Fig 21E). This was 
shown to be synergistic, and higher doses of both carfilzomib and cyst(e)inase induced 
lower CI values and stronger synergy (Fig 21F). Cell cycle analysis showed that DIPG 
IV cells in the G2/M phase were preferentially killed by the combination treatment after 








Figure 21. Cyst(e)inase depletes glutathione and has moderate synergy with carfilzomib 
in DIPG IV cells. (A) Dose response curves for viability of 3 proteasome inhibitors in 
adult GBM (LN18) and 3 pediatric DIPG lines. (B) Dose response of cyst(e)inase in 
DIPG IV for viability and growth. (C) GSH assay for glutathione level after dosing with 
cyst(e)inase in LN18 and DIPG IV. (D) Viability of LN18 cells dosed with combinations 
of proteasome inhibitors and cyst(e)inase. (E) Viability and growth of DIPG IV cells 
dosed with combinations of carfilzomib and cyst(e)inase. (F) Synergy calculations of 
viability for DIPG IV treated with carfilzomib and cyst(e)inase. Viability values were 
entered into CalcuSyn software (Biosoft) and combination analysis was run to generate 
CI values. >1 is considered antagonistic, <1 is considered synergistic. (G) Cell cycle plot 
of DIPG IV treated with 10nM carfilzomib and 25 or 50nM cyst(e)inase. * = p < 0.05 via 





In conclusion, my data shows that some DIPG cells maintain the sensitivity to 
proteasome inhibitors that was observed by Dr. Manton in her adult glioblastoma cells. I 
could also confirm that cyst(e)inase depletes GSH in a dose-dependent manner in 
DIPG cells. While cyst(e)inase did not induce cell death as a single agent, it was a 
potent inhibitor of cellular proliferation. Combination treatment of DIPG IV cells with 
cyst(e)inase and carfilzomib was synergistic for cell viability, and preferentially depleted 
cells in G2/M phase of the cell cycle. This suggests that cell death may occur during 
mitosis and lack of cystine may be important for cell division. While this result is 
interesting, the therapeutic window for this synergism is narrow, mainly occurring at 
viabilities around the IC50 of the proteasome inhibitors. Despite this, further testing of 
the cyst(e)inase as a therapeutic for gliomas is warranted given it has been used in 
prominent studies as an anti-cancer agent against prostate, breast, chronic lymphocytic 
leukemia (181), and pancreatic (182, 183) cancers. Furthermore, it was shown that 
metabolic catastrophe can enhance the effect of proteasome inhibitor marizomib 
against DIPG, at least in part by depletion of nicotinamide adenine dinucleotide (NAD+) 
by combination therapy with HDAC inhibitors (184).  
A critical oversight of their paper was the strong induction of the pentose-
phosphate pathway (PPP) under combination treatment with panobinostat and 
marizomib. They also observed reductions in GSH and increases in GSSG, but could 
not rescue viability with NAC; however, they used an incredibly low dose of 50µM NAC, 
which must be used in the millimolar range to produce more GSH. A high GSSG/GSH 
ratio also can suggest glutathione cannot be recharged by NADPH normally generated 
by the PPP. NADPH levels were observed to be reduced under combo treatment, so 
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despite high expression of PPP enzymes, normal metabolites are not produced (184). 
Glucose is the PPP substrate shared with glycolysis, and glycolysis was also reduced 
under combination treatment, suggesting glucose availability via glucose transporters 
(GLUT1-4) may be affected by this treatment. I would hypothesize that ROS induction 
by pano+marizomib treatment triggers upregulation of the PPP to supply more NADPH 
for GSH recharge, but glucose cannot be imported, leaving the cells under oxidative 
stress that might be rescued with exogenous glutathione or NAC (at an appropriate 
dose). The authors did not measure ROS in this manuscript, and it has been shown that 
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